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ABSTRACT
Development of improved T cell receptor beta variable gene identification
technology and its application post hematopoietic stem cell transplantation

Jamie Leigh Brewer
Much has yet to be understood about the role of specific families of T
lymphocytes in the post human hematopoietic stem cell (HSC) transplant environment.
Prior work in the field has identified T cells based upon the expression of their T cell
receptor beta variable regions (TCRBV). In this investigation we developed a
comprehensive panel of oligonucleotides that can be used to determine the expression
of all 91 alleles of the human TCRBV regions using real time PCR technology.
Application of this technology to peripheral blood samples collected weekly from
allogeneic peripheral blood stem cell transplant patients yielded the following findings:
(1) specific TCRBV families are associated with the reactivation of cytomegalovirus
(CMV) post HSC transplant with many of these same TCRBV families also being
associated with the occurrence of GVHD, (2) the TCRBV repertoire engrafts in the
recipient with a profile more similar to that found in the donor as opposed to that found
in the recipient prior to transplant, and (3) the similar immunosuppressive agents,
cyclosporin A (CSA) and tacrolimus (FK506), differentially alter the TCRBV repertoire
with their administration, a difference which can not be attributed to a divergent
inhibition

of

calcineurin

or

IL-2

production

by

CSA

or

FK506.
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CHAPTER 1

REVIEW OF LITERATURE

1

I. The History of Hematopoietic Stem Cell Transplantation
Many advancements in the field of hematopoietic stem cell transplantation were
borne from the seemingly unrelated birth of nuclear technologies. With the development
of atomic technologies and the potential of nuclear warfare, the effects of irradiation on
biological systems became an area of imminent interest 1. This resulted in a series of
experiments conducted over the past fifty years and has greatly increased our
understanding

of

hematopoietic

stem

cell

transplant

and

the

immunological

mechanisms that are so critical to its success.
The modern epoch of bone marrow transplantation was pioneered by Lorenz in
1951 when he demonstrated that mice could be protected against lethal irradiation by
intravenous infusion of bone marrow 2. This discovery quickly brought about the notion
that hematological malignancies could potentially be cured through irradiation and
subsequent marrow grafting. Barnes, et al., showed that murine leukemia could be
successfully treated using sub-lethal doses of irradiation followed by the infusion of
healthy marrow 3. The following year, the first reports detailing similar clinical trials in
humans were made, describing the immediate rescuing from radiation-induced
pancytopenia in cancer patients by marrow infusion

4,5

. In 1959, Mathe et al., attempted

bone marrow transplantation in humans on a larger scale when they tried to rescue six
victims of a radiation accident in Vinca, Yugoslavia, by transplanting allogeneic bone
marrow 6. This group continued trying to use bone marrow transplantation as treatment
for hematologic malignant conditions, however, it was not until 1963 that they reported
the first case of a patient surviving beyond a year. While this patient remained leukemiafree, severe graft-versus-host disease (GVHD) reactions were documented, the first of
such, and the patient succumbed to infection 20 months post-transplant 7.
II. Types of Hematopoietic Stem Cell Transplantation
There are three primary types of hematopoietic stem cell transplants depending
upon the stem cell source and the identity of the donor. These are termed autologous,
allogeneic, and syngeneic transplants. The first type, autologous transplant, describes
the process where an individual serves as his/her own stem cell source. In order for an
autologous stem cell transplant to be successful, the individual’s marrow must be
virtually disease free prior to harvesting. An example of the use of this type of transplant

2

is one in which a patient must undergo intensive treatment directed at his/her tumor,
which, as a consequence, would inadvertently cause destruction to his/her
hematopoietic system. After the high-dose tumor therapy, the patient can then be
infused with the previously collected stem cells to rescue his/her hematopoietic system.
Autologous transplants are now most frequently used for hematologic malignancies
such as lymphomas. Advantages to autologous transplantations are that there is no
need to locate a suitable stem cell donor as well as a decreased risk of treatmentrelated mortality. Such transplants, however, have a risk of tumor cell contamination in
the graft. Additionally, autologous transplants cannot be used in the treatment of
inherited non-malignant hematopoietic diseases or acquired marrow failure states, such
as aplastic anemia 8.
The second major type of hematopoietic stem cell transplant, termed an
allogeneic transplant, is one in which the stem cell donor is separate from the recipient.
The donor must be genetically matched to the recipient but the two can either be related
or unrelated. Advantages of this type of transplant are that there is a low risk of the graft
being contaminated with malignant cells and it can successfully be used in treating both
malignant and non-malignant diseases of the hematopoietic system. An additional
advantage to allogeneic transplant is the possible destruction of residual recipient tumor
cells by the infused donor-derived cells, an occurrence termed graft-versus-tumor effect.
Despite these advantages, however, there is often great difficulty in finding an
appropriate donor and there is a greater increase, compared to autologous transplants,
of post-transplant complications, such as graft-versus-host disease 8.
The third major type of hematopoietic stem cell transplant is one in which the
donor and recipient are genetically identical, such as the case that occurs when the
recipient and donor are identical twins, and is termed a syngeneic transplant. Post
transplant complications tend to be diminished in this setting, compared to a nonidentical allogeneic transplant, but while the majority of patients may have a sibling, it is
relatively uncommon for the sibling to be an identical twin 8.
Traditionally, hematopoietic stem cells (HSC) have been harvested from bone
marrow through extraction at the iliac crests. Recent advancements in transplantation
technology, though, have permitted the mobilization of hematopoietic stem cells from

3

the bone marrow environment to the peripheral circulation through the use of growth
factors such as granulocyte colony stimulating factor (G-CSF) 9-13. HSC comprise only a
small fraction of the total number of cells in the bone marrow, with a rate of
approximately one HSC/10,000 total bone marrow cells and the number of HSC
circulating in the peripheral blood is an exceedingly rare event

14

. After G-CSF

administration, however, the frequency of HSC in the peripheral blood is increased two
to five-fold greater than that found in the bone marrow

15

. Mobilized HSC can then be

harvested from the peripheral blood by a pheresis procedure. A dose of at least five
million HSC/kg recipient weight has been reported to be the ideal dose to achieve
engraftment 16.
While multiple collections may be required in order to achieve the necessary
number of stem cells for transplant using the G-CSF mobilization technique, there is a
low toxicity profile associated with G-CSF administration in humans

10-13

. The side

effects are generally limited to bone pain and general influenza-like symptoms and there
have been no documented reports of termination of G-CSF administration to healthy
donors due to its side effects. Thrombocytopenia, or the reduction in platelet number, is
frequently observed post-pheresis in G-CSF mobilized donors. This reduction, as well
as any bone discomfort, is generally reversed within 48 hours of cessation of drug
administration. On the other hand, while bone marrow harvests require no mobilization
therapies and can often be done in a single one-day collection, the pain associated with
bone marrow harvests may take 2 to 4 weeks to subside

17,18

. In addition, various

studies have reported a decreased time for reconstitution of the immune system, less
transplant-related toxicities and mortalities, and a decreased rate of GVHD occurrence
in peripheral blood stem cell recipients compared to bone marrow recipients 19-23.
The benefits of peripheral blood stem cell harvesting, compared to bone marrow
harvesting, have resulted in peripheral blood stem cell transplantation becoming much
more frequently used compared to bone marrow transplantation. HSC have also been
collected from umbilical cord blood and used successfully in allogeneic transplantation.
While cord blood HSC have decreased alloreactive potential compared to their
counterparts isolated from more mature donors, cord blood stem cells exhibit a delayed

4

reconstitution of the hematopoietic system, thereby limiting their usage in hematopoietic
stem cell transplantation 24-30.
In allogeneic transplants the conditioning regimen the recipient receives prior to
transplant is highly dependent upon the type of disease the patient has as well as how
aggressively it behaves

31

. There are three main objectives to the treatment. The

primary objective is to eradicate the underlying hematological disease in the recipient.
The second objective is to suppress the recipient’s immune system to decrease the risk
of the recipient rejecting the donor’s stem cells. The third objective in using a
conditioning regimen pre-transplant is to create space in which the donor’s stem cells
can engraft and growth can be accommodated

32

. While the amount of time required for

immune reconstitution post hematopoietic stem cell transplant varies depending upon
parameters

such

as

the

type

of

transplant,

conditioning

regimens,

and

immunosuppressive therapies, CD8+ T cell counts tend to recover to normal values
within the first month post transplant with a prolonged deficiency of CD4+ T cell counts
often seen six to twelve months post transplant, leading to the characteristic inversion of
the CD4:CD8 ratio observed post transplant 33-37.
III. HLA
Based on experiments initially performed in mice

38

antigenic principles

underlying cellular transplantation began to be established. Such experiments led to the
recognition of what became termed the H2 transplantation antigen system
and the HLA system in humans

40

39

in mice

. The human leukocyte antigen (HLA), also termed the

major histocompatibility complex (MHC) forms a complex which is expressed on the
cellular surface. The principle function of this molecule is to present peptides (from
either self or non-self origin) to T lymphocytes, a vital component to the immune system.
By doing so, the T lymphocytes are able to distinguish self versus non-self. An
illustration of this principle is afforded by examining what occurs during a viral infection:
if a cell is infected with a virus, pieces of viral proteins (non-self) are loaded into the
MHC molecule and presented on the surface of the infected cell. The interaction of a
circulating T cell with this (non-self) MHC molecule can activate the T cell, causing it to
destroy the infected cell, thereby limiting the spread of infection. The same is true in the
setting of transplantation. T cells in the donor graft can recognize cells within the
5

recipient’s body as non-self, eliciting devastating immune reactions. This is the premise
of a serious post-transplant complication called graft-versus-host disease (GVHD) 41.
There are three classes of HLA (or MHC) genes, termed class I, class II, and
class III genes, with all three being located on chromosome 6 in humans. The names
HLA-A, HLA-B, and HLA-C are given to the human MHC class I genes while the MHC
class II genes are identified as HLA-DR, HLA-DP, and HLA-DQ. The products of these
MHC class I genes are expressed on the surface of nearly all cells within the human
body while the expression of the MHC class II genes is restricted to antigen presenting
cells and thymic epithelium. Classically, MHC class I proteins present endogenous
antigen (or peptide) to CD8+ T cells while the MHC class II proteins present exogenous
antigen (or peptide) to CD4+ T cells. The final class of genes, those located within the
MHC class III region, encode various immunologically relevant proteins such as
complement and the tumor necrosis factor cytokines 42.

Figure 1: Gene structure of the human major histocompatibiltiy complex (MHC)

The HLA genes are expressed in a co-dominant fashion and are highly
polymorphic

43

. In terms of their importance in hematopoietic stem cell transplantation,

matching at the MHC class I HLA-A and HLA-B loci was given priority as previously
there had been a lack of reagents available to accurately determine the HLA-C
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genotype. Due to the advancements of molecular biology, however, such discrimination
is now possible. In fact, recent reports have been made concerning the importance of
HLA-C matching in hematopoietic stem cell transplantation

44-46

. As it relates to the

MHC class II molecules, allelic mismatching of the donor and recipient at the HLA-DR
loci was the first to be shown to be associated with an increase in graft-versus-host
disease reaction
apparent

48

47

. The importance of HLA-DQ matching is also becoming more

. However, like its MHC class I counterpart (HLA-C), mismatching at the

HLA-DQ locus has yet to become a basis for donor exclusion. The role of HLA-DP in
transplantation has remained rather controversial and is also not typically evaluated
when searching for an appropriate donor

49

. In summary, the common practice of HLA

matching in related donor and recipient has remained matching of the HLA-A, HLA-B,
and HLA-DR loci, although typing of additional loci is commonly performed when an
unrelated donor is being considered. Likewise, HLA matching is typically performed
using serological methods when the donor is related and by molecular analyses when
the donor and the recipient are not related.
IV. T Cells
On the converse side of the MHC molecule is the T cell, whose interaction with
the MHC molecule is mediated
through the T cell receptor
(TCR). T lymphocytes originate
in the bone marrow from a
lymphoid progenitor cell and
migrate to the thymus as
immature cells. The thymus
provides

a

unique

microenvironment in which the
T lymphocyte rearranges its
receptor genes (chromosome
14, TCR alpha genes and
Figure 2: T cell receptor (TCR) gene rearrangement

chromosome

7,

TCR

beta

7

genes

50

) and matures. T cell receptor (TCR) gene rearrangement occurs in the sub

capsular region of the thymus with rearrangement of the heavy chain (or beta chain)
genes occurring prior to rearrangement of the light chain (or alpha chain) genes. Within
the T cell receptor beta chain locus, a diversity (D) segment is randomly paired with a
joining (J) segment. This DJ unit is then rearranged with a variable (V) segment to form
a VDJ segment. The constant (C) region exon is then spliced to the VDJ segment to
generate the message, which is translated into the T cell receptor beta chain protein.
Beta chain gene rearrangement is followed by rearrangement of the TCR alpha chain,
which occurs in the same manner as for the heavy chain. However, as there is no
diversity region in the light chain, rearrangement of the variable and joining segments is
followed by the VJ pairing with a constant (C) segment 50-52.
After the heavy and light chain rearrangements occur, the T cell begins to
undergo maturation and moves deeper into the thymus. In the cortex of the thymus the
immature cells undergo positive selection where only those developing cells that
recognize antigens presented by self-MHC molecules can mature. Those T cells that do
not recognize antigen in the context of a self-MHC molecule are deleted by apoptosis.
As the positively selected thymocytes move into the cortico-medullary junction of the
thymus they undergo negative selection where those that recognize self-antigens too
well are deleted. Negative selection helps to remove auto-reactive T cells from the
repertoire. Finally, those thymocytes that have survived both positive and negative
selection exit through the medulla of the thymus and enter the peripheral circulation
where they traffic through secondary lymphoid organs monitoring the body through T
cell receptor:peptide:MHC interactions

50-52

. The significance of the wide variety of MHC

molecules (more than fifty alleles at each of the HLA-A, HLA-B, and HLA-DR loci
identified

53

) and possible TCR rearrangements (24 million

54

) is critical to the ability of

an individual’s immune system to respond to a wide variety of pathogens.
With an understanding of the molecular interaction between the MHC molecule
and the TCR, the importance of T cells in the post hematopoietic stem cell transplant
setting becomes clearer. Investigations into these reactions and their role in graft
rejection and graft-versus-host disease were made as early as 1963 7,55.

8

V. GVHD
Hematopoietic stem cell transplant offers patients a potential for recovery from
otherwise lethal conditions. However, associated with this possibility is the threat of
graft-versus-host disease (GVHD), a reaction where the transplant recipient’s tissue is
attacked and destroyed by the infused donor cells. GVHD-like reactions have been
observed in mice that had been treated with allogeneic marrow after irradiation. While
these mice recovered from their marrow ablation, the mice died from what was termed
“secondary disease”, now known as graft-versus-host disease 41, a condition marked by
weight loss, diarrhea, and liver and skin changes 56,57.
In 1957, such observations in mice led Billingham to establish criteria essential
for the development of graft-versus-host disease. The first of these criteria is that the
graft must contain immunologically competent cells. Secondly, the recipient of this graft
must not be able to mount an immune response against these transplanted cells, which
would lead to their ultimate destruction. Finally, the recipient must also express antigens
that are not present in the donor graft 58.
Billingham’s first requirement was further understood when in 1962, Gowen
identified the cells responsible for GVHD as small lymphocytes

59

, but it was not until 25

years after these first observations that the “immunologically competent cells” were
actually identified as T lymphocytes

60

. In 1986 Kernan demonstrated a direct

correlation between the severity of GVHD and the number of donor T cells transfused
67

. Attempts have been made to T-cell deplete grafts (ex vivo) prior to transplant which

decreases the risk of GVHD, and to then use “add-backs” of donor lymphocytes post
transplant in order to promote the graft-versus-tumor effect

61-79

. The complete removal

of T cells from the graft, however, has been shown to cause an increase in graft failure
and is, therefore, not a practical option 80,81.
Billingham’s second requirement of the recipient being devoid of immunocompetent cells is typically not of great concern in hematopoietic stem cell
transplantation as recipients classically receive intense immunosuppressive treatments
in order to prevent the recipient-mediated rejection of the donor cells 82-84.

9

With the discovery of the MHC genes and the role that they play in
transplantation, an increased understanding of Billingham’s third requirement was
achieved. As previously discussed, these MHC molecules are necessary for activation
of T cells, in both autologous and allogeneic transplant settings

85

. In allogeneic

transplants the matching of the donor and recipient’s HLA antigens is one of the
foremost criteria in selecting an appropriate hematopoietic stem cell donor. It has been
observed, though, that even with matching of these antigens, GVHD reactions can still
occur

86

and have been attributed to what have been termed minor histocompatibility

antigens.
Minor histocompatibility antigens, or mHA, have been defined as a non-MHC
locus that can elicit allogeneic tissue rejection 87,88. Minor histocompatibility antigens are
inherited and are not necessarily in close proximity to the HLA genes
shown that certain MHC present specific mHA
from specific TCRBV

92

90,91

89

. It has been

and specific mHA elicit responses

. There have been seventeen minor histocompatibility antigens

identified thus far, with the expression of twelve of these being restricted to cells of the
hematopoietic lineage 91,93,94. At the present time, while it is known that mHA differences
can contribute to GVHD, it is difficult to predict the outcome of a hematopoietic stem cell
transplant based upon identification of these minor histocompatibility antigens 95,96.
One model describes the development of GVHD as occurring in two phases: the
afferent and efferent phases. The afferent phase consists of the damage incurred to the
recipient both by the pre-transplant conditioning regimens (chemotherapy/radiation) as
well as by the activation of the donor T cells. It has been shown that the conditioning
regimens cause damage to and activate tissues within the recipient, including the tissue
of the gastrointestinal tract as well as the liver 97-100,. Such damage results in the release
of LPS and inflammatory cytokines, such as IL-1, tumor necrosis factor (TNF) alpha,
and interferon (IFN) gamma, from the activated tissues which causes the subsequent
activation of host antigen presenting cells

23,101-112

. Further complicating these

circumstances is the fact that LPS and IFN gamma can act in a synergistic fashion,
additionally increasing the levels of pro-inflammatory cytokines such as TNF alpha

113

.

In addition it has been shown that the administration of antagonists to LPS, as well as to
the receptors for these inflammatory cytokines, has ameliorated the effects of GVHD

10

103,105,110,114

. The important role of LPS in GVHD is also supported by the observation

that pathogen-free mice have reduced incidence of GVHD after allogeneic transplant
115,116

.
The efferent stage of GVHD is comprised of the actual destruction of the

recipient tissues by activated T lymphocytes responding to allogeneic antigens

117

. A

combination of the afferent and efferent stages contribute to the devastation seen in
GVHD.
GVHD can present itself in two forms, acute and chronic. Acute GVHD presents
within the first 100 days post-transplant whereas the chronic form appears post day
100. The pathology of the two forms show similarities, however 41.
There are four grades of acute GVHD: I-IV, with IV being the most severe. While
the development of GVHD grade I or II is associated with an increased risk of
developing GVHD grade III or IV, little morbidity is associated with GVHD grade I.
However, much greater levels of morbidity are seen with the progression of GVHD to
grades II and III, and grade IV GVHD represents a life threatening condition 41.
In acute GVHD the primary target organs are the skin, gastrointestinal tract, and
liver, with the skin being the most easily observed and often first diagnosed target
organ. In the skin, GVHD presents as erythema and rash, commonly located on the
palms and soles initially, but can spread to involve the rest of the body. In severe
situations, the skin may actually become desquamated (grade IV). In terms of its effect
on the gastrointestinal tract and liver functioning, symptoms include nausea, vomiting,
diarrhea and hyperbilirubinemia. In each instance, with increased severity of these
symptoms or worsening laboratory findings, the higher the grade of GVHD 41.
VI. Immune Suppression
Allogeneic hematopoietic stem cell transplant recipients are routinely given
immunosuppressive agents to facilitate engraftment and decrease the risk of developing
GVHD post transplant. Cyclosporin A (CSA), tacrolimus (FK506), and methotrexate, are
examples of such agents. CSA and FK506 have similar mechanisms of action, which is
to bind to cyclophilin or FK binding protein (FKBP), respectively; the resulting drugprotein complexes inhibit calcineurin activity

118-128

. The protein calcineurin is directly

involved in the transcription of cytokines, such as IL-2. Through the administration of
11

CSA or FK506 it is possible to inhibit expansion of allo-reactive T cells and their
reactions post transplant. CSA and FK506 treatment is begun one day before transplant
(d-1) and continues throughout the post transplant period.
The mechanism of methotrexate, pulses of which the patients receive as part of
standard GVHD prophylaxis, is through the inhibition of dihydrofolate reductase, the
enzyme responsible for purine and pyrimidine synthesis, which leads to the suppression
of T cell activation and adhesion molecule expression

129

. Methotrexate infusions are

administered on days 1, 3, 6, and 11 post-transplant as standard GVHD prophylaxis.
While immunosuppressive agents such as these help to prevent graft rejection
and GVHD, such suppression makes it difficult for the patient to mount immune
responses against invading pathogens and also makes the patient more susceptible to
the reactivation of latent infections, such as cytomegalovirus.
VII. Infection Susceptibility
After hematopoietic stem cell transplant patients are highly susceptible to
bacterial, viral, and fungal infections. To decrease the risk of overwhelming infections
post-transplant, patients receive prophylactic antibiotics. Use of prophylactic anti-fungal
agents, such as fluconozole, decreases the occurrence of fungal infections, but in spite
of the use of prophylactic antifungal therapy, patients can develop fungal infections
including those attributed to Candida and Aspergillus species

130

. Examples of bacterial

infections that are commonly observed post transplant include both gram positive
(Staphyloccocus, Enterococcus, Clostridium, and Corynebacterium) and gram negative
bacteria (Haemophilus and Escherichia). As previously mentioned, reactivation of latent
cytomegalovirus (CMV) is a common occurrence post hematopoietic stem cell
transplant 130.
VIII. Identification of T Cells Involved in GVHD Through TCRBV Analysis
In graft-versus-host disease (GVHD), the donor T cells recognize the host
(recipient) MHC molecule as foreign, causing destruction of the cells expressing the
allo-reactive molecule. Such reactions are also important in the recipient’s defense
against reactivation of latent infections such as CMV. Since it is the variable region of
the TCR that is in intimate contact with the MHC molecule, determining what specific
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variable families of T cells can be linked to the destructive effects of GVHD has been a
focus of investigation 131-143. Due to the prior lack of standardized nomenclature for TCR
gene families, classification of the variable region data has become complicated
because different investigators named the same family different names and, conversely,
different families were named the same. To resolve this classification dilema an
international team was formed to assign consistent and systematic names to all of the
TCR variable gene segments. Bernhard Arden published the results in 1995

144

. At

present, there are 32 functional alpha TCR variable families in humans with 69
subfamily members and 25 functional beta TCR variable families in humans with 91
subfamily members. As antibodies recognizing all of these TCR variable families are not
available, an alternative approach is to use RT-PCR to evaluate the expression of the
messages (mRNA) used to make these surface proteins. Primer panels previously
designed to detect the wide range of TCR variable families do not, however, detect all of
the TCR variable families outlined in the Arden paper

138,145-189

, due to the unavailability

of the classification system at the time of primer development or the labor-intensive task
of developing and validating a truly complete primer panel.
IX. Summary
Since its early inception, bone marrow transplantation has been used to treat
conditions ranging from exposure to a radiation accident in the late 1950s to treating
conditions such as leukemia and lymphoma, aplastic anemia, as well as immunedeficiency disorders such as congenital neutropenia in the twenty first century 6.
Despite advancements in the field of hematopoietic stem cell transplantation,
serious complications can still occur post transplant. These include the occurrence of
GVHD, severely immune-suppressed states that can lead to reactivation of latent
infections such as CMV, and therapeutic agent toxicities 13,130,190.
If it is possible to determine prior to transplant the GVHD-causing T cells, those
cells can be depleted or inhibited prior to blood or marrow infusion, thereby preventing
the development of GVHD. Experiments performed in mice have demonstrated that
when TCR variable families have been identified as being implicated in GVHD, those
cells can be depleted prior to transplant, preventing development of a graft-versus-host
reaction

191

. In addition, those cells can be adoptively transferred into a lethally
13

irradiated host and initiate a graft-versus-host disease reaction

192

. Should trials in

humans yield such predictable results, blood and marrow transplantation could become
a treatment modality with a much-decreased risk of morbidity and mortality and offer
hope of a cure to more patients.
X. Research Objectives
The main objective of the work presented in this dissertation is to understand the
role of specific groups of T cells after hematopoietic stem cell transplantation in
humans. The importance of T cells post hematopoietic stem cell transplantation has
long been recognized. There is a significant lack of understanding, though, as to the
role specific T cells play in this setting. This project will determine the role of specific T
cells, as identified by expression of their T cell receptor beta variable region, in certain
post hematopoietic stem cell transplant events. This dissertation will detail the following
objectives:

1. Develop a methodology to accurately detect expression of all the human TCRBV
families. Many previous investigations have detailed molecular based methods
used to identify the various TCRBV families in humans. These reports fail to
account for the standardized classification of the TCRBV genes by the World
Health Organization and often leave specific subfamilies and alleles undetected.
Serological methods, such as antibody staining, have also been employed by
prior studies. This method, too, lacks the ability to detect all of the human TCRBV
genes. We aimed to develop a modern molecular based method that can
specifically detect all alleles of the human TCRBV repertoire.

2. Utilizing technology developed in objective 1, determine the association of
specific T cell with the following post hematopoietic stem cell transplant related
events:
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a. Graft-Versus-Host Disease (GVHD)
GVHD is a common post hematopoietic stem cell transplantation
complication and we aim to determine if specific families of T cells are
associated with the occurrence of this condition.
b. Cytomegalovirus (CMV) reactivation
During the immune suppressed state post transplant, patients often
experience reactivation of latent infections, such as CMV, which contribute
additional complications to the recovery stage. GVHD and CMV have
been linked to each other in previous reports. We aim to determine (1)
what specific families of T cells are associated with reactivation of CMV
post transplant and (2) if there is any overlap in the T cells associated with
both GVHD and CMV.
c. Immunosuppressive therapies Cyclosporin A (CSA) and tacrolimus (FK506)
Immunosuppressive therapies, such as CSA and FK506, are administered
post hematopoietic stem cell transplant to curtail the development of graft
rejection and graft-versus-host disease. These agents target activated T
cells through their suppression of IL-2 production. We aim to determine if
the effects of these agents on the TCRBV repertoire is the same with both
CSA and FK506.
d. Correlation of engraftment profiles to baseline donor and recipient samples
It is not known whether the identity of the engrafting TCRBV repertoire is
more like that found in the recipient prior to transplant or if it mimics that
found in the donor. We aim to determine the answer to this question.
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AN IMPROVED METHODOLOGY TO DETERMINE HUMAN TCRBV
GENE EXPRESSION
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ABSTRACT
Comprehensive gene expression analysis of the T cell receptor repertoire of an
individual can be very useful in evaluating the immune response in a variety of
conditions. Antibody based analysis methods can detect approximately sixty percent of
the human T cell receptor beta variable (TCRBV) proteins, while gene expression
analysis, primarily through employment of the polymerase chain reaction (PCR), has
had somewhat greater success in the detection of additional TCRBV families. Many of
these previous PCR methods, however, have been unable to detect all 91 alleles of the
human TCRBV genes. This is primarily due to either deficiencies in the amplification of
all of the variable beta families, subfamilies, and alleles, or the prior lack of a systematic
classification of the TCR variable family gene segment sequences. We describe here a
real time reverse-transcription polymerase chain reaction based method, which allows
efficient automation and integration of amplification, detection, and analysis with
sequence specific detection of all T cell receptor beta variable gene families,
subfamilies, and alleles. This method, which in itself contributes significant
improvements over existing technologies through its comprehensiveness and efficiency,
also functions independently of variables such as sample source and sample
processing and has the ability to run on multiple real-time PCR platforms, affording one
the implementation of personal preferences.
INTRODUCTION
T cells constitute a component of the immune system that is able to distinguish
“self” versus “non-self”. This is accomplished through the interaction of their T cell
receptor (TCR) with the antigen:major histocompatibility complex (a:MHC) expressed on
the surface of cells. The αβ T cell receptor is a heterodimer, one component of which is
a beta (B) chain, consisting of both a variable (V) and a constant (C) region. It is the
variable region of the chain that directly contacts the a:MHC, eliciting the T cell
response. Each individual has multiple TCRBV gene segments (or families) allowing for
the ability to respond to a large number of a:MHC complexes 1.
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A primary way to analyze the T cell receptor repertoire in an individual is through
the use of antibody-based methods. Antibody based analysis methods can detect
approximately sixty percent of the human T cell receptor beta variable (TCRBV)
proteins, while gene expression analysis, primarily through employment of the
polymerase chain reaction (PCR) 2, has had somewhat greater success in the detection
of additional TCRBV families. Many of these previous PCR methods, however, have
been unable to detect all 91 alleles of the human TCRBV genes. Such a comprehensive
PCR strategy, however, requires the usage of both uniform and systematic
organizations of the TCRBV genetic sequences. Such a TCRBV classification system
was established by the World Health Organization (WHO) and has resulted in the
identification of 25 different functional B variable families (with 91 subfamily and allele
members total)3. Based on the WHO classification of the TCRBV families, two
sequences reside within the same family if there is at least 50% homology between the
two sequences. Subfamily members share at least 75% sequence homology and alleles
of a given TCRV gene differ at no more than a few residues 3.
Previous attempts at establishing PCR-based methods to evaluate the
expression of all members of the TCR families have not taken into account the new
WHO systematic classification or the wide variety of subfamilies and alleles that exist for
many of the variable families
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. When possible, such references were consulted for

potential primer sequences. However, many of those sequences did not satisfy the
requirements of amplifying all of the various subfamilies and alleles within a given
variable family or they inadvertently cross-amplified the sequence of a closely related
variable family. The generation of a comprehensive panel of TCRBV primer sequences
presented a significant challenge as the TCRBV families all share nearly 50% homology
with each other and sequences designed to detect a specific family can inadvertently
cross-amplify a closely related TCRBV family. We designed primers that will specifically
detect all known alleles within the identified TCRBV families and, when possible, we
designed a single primer to detect all alleles of a given TCRBV family, thereby
improving on previous panels that required using multiple primer sequences to amplify
multiple alleles of a given TCRBV family. In addition, some of the primer sequences
from previous panels, while potentially meeting our stringent specificity requirements,
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had a melting temperature that fell outside of our desired ten-degree melting range of
55oC to 65oC, making it difficult to analyze expression of all of the TCRBV families in a
single experiment with a single amplification cycling protocol.
We describe here how we have established a complete panel of PCR primers
that can be used with sequence specific real-time PCR methodology to evaluate the
expression of all the TCRBV gene families, including all subfamily and allele members.
The user has the flexibility of using many sample sources and processing methods, as
well as benefiting from automated and integrated amplification, detection, and analysis
in a gel free environment on a wide variety of real time PCR platforms. The technology
can be applied to any area of study examining T cell biology, including autoimmunity,
transplantation, cancer therapy, and infectious disease.
MATERIALS AND METHODS
Primer and Probe Development
Primer sequences were developed using the TCRBV classification system
described by Arden, et al. 3. Sequences were analyzed and potential primer sequences
were evaluated for cross-reactivity using GenBank’s BLAST tool (National Center for
Biotechnology Information, http://www.ncbi.nlm.nih.gov/BLAST/). Human 18S rRNA
primers and TaqMan® probe were designed using Beacon Designer 2 software
(PremierBiosoft International, Palo Alto, CA, USA). TaqMan® probes were analyzed for
cross-reactivity using GenBank’s BLAST tool (National Center for Biotechnology
Information).
Peripheral Blood Samples
A volume of ~20 mL of peripheral blood was collected, via venipuncture from
individual healthy donors and from a hematopoietic stem cell transplant patient, into
acid citrate dextrose VACUTAINER™ blood collection tubes (Becton Dickinson,
Franklin Lakes, NJ, USA). Informed consent was obtained from participants after the
nature and possible consequences of the study had been fully explained according to
West Virginia University’s Internal Review Board guidelines. Buffy coat layers were
isolated via centrifugation at 3300 rcf for 10 minutes. Contaminating red blood cells
were removed by hypotonic lysis.
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Flow Cytometric Analysis
Peripheral blood composition was determined by light scatter profiling using a
CELL-DYN 3500 (Abbott Diagnostics, Santa Clara, CA, USA). Additional classification
of the lymphocyte population was performed by cell surface staining using antibodies
specific to CD4 (Beckman Coulter, New York, NY, USA), at a volume of 20 µL antibody
per 5 x 105 cells, CD8, and CD19 (Caltag Laboratories, Burlingame, CA, USA), both at
antibody concentrations of 1 µg per 1 x 106 cells. Cells were blocked prior to antibody
addition by incubating cells for five minutes at room temperature with human IgG at a
concentration of 200 µg per 5 x 105 cells (Sigma Chemical Co., St. Louis, MO, USA).
After antibody addition, cells were incubated 30 minutes in the dark at room
temperature followed by a single wash with 1x PBS. The stained cells were then fixed in
500 µL of 1% paraformaldehyde. All prepared samples were analyzed by flow
cytometric analysis using a FACScan™ (Becton Dickinson), which had been calibrated
using three color Calibrite™ Beads (Becton Dickinson) and FACSCOMP™ software
(Becton Dickinson). For further lymphocyte analysis of CD19+, CD8+, and CD4+
expression 10,000 total events were collected for each sample. SSC and FSC data
were acquired in the linear mode and the FL1, FL2, and FL3 parameters were collected
logarithmically. Data analysis was performed using Windows Multiple Document
Interface (WinMDI) version 2.8 (Joseph Trotter, The Scripps Research Institute,
http://facs.scripps.edu/software.html).
RNA Isolation
Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent
according to the manufacturer’s directions (Ambion, Austin, TX, USA). RNA was
dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA
according to the manufacturer’s recommendations using DNA-free™ (Ambion). RNA
purity and concentration was determined by standard 260nm:280nm spectrophotometric
analysis using a Genesis 10UV Spectronic Unicam (Spectronic Instruments, Rochester,
NY, USA).
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RT-PCR
One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit
(Qiagen, Valencia, CA, USA). Recommended reaction mixtures were scaled down to a
total reaction volume of 20 µL using 0.04 µg RNA with the following primer and probe
concentrations: 0.4 µM TCRBV primer (Biosource International, Camarillo, CA, USA),
0.4 µM TCRBC primer (Biosource International), and 0.2 µM TCRBC TaqMan® probe, 5’
6-FAM, 3’ BHQ™-1 (Integrated DNA Technologies, Inc., Coralville, IA, USA). 18SrRNA
control reactions were performed in parallel using 0.4 µM each of sense and anti-sense
primers (Biosource International) and 0.2 µM 18SrRNA TaqMan® probe, 5’ 6-FAM, 3’
BHQ™-1 (Integrated DNA Technologies, Inc.).
An iCycler™ (BioRad Laboratories, Hercules, CA, USA) was used for the RT and
amplification cycles. RT was performed at 50oC for 60 minutes, max ramp speed,
followed by an initial Taq DNA polymerase activation step of 15 minutes at 95oC, max
ramp speed. A TouchDown PCR approach
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was used with the following cycling

o

conditions: denaturation for 15 seconds at 95 C, max ramp speed, annealing for 30
seconds starting at 70oC decreasing by 2oC for 10 repeats, max ramp speed, and
extension for 40 seconds at 72oC, min ramp speed. After this TouchDown of the
annealing temperature, 50 cycles were performed as follows with the optical data
collection occurring at the extension step: 15 seconds at 95oC (max ramp speed), 30
seconds at 52oC (max ramp speed), and 40 seconds at 60oC (min ramp speed).
Reactions were held at 4oC upon the conclusion of the run. Amplification efficiencies
using cDNA dilutions were determined using the above described cycling protocol with
the deletion of the reverse transcription cycle of 50oC for 60 minutes.

cDNA isolation
PCR products were electrophoresed on a 2% agarose gel using 20 µL PCR
product and 4 µL tri-color 6X loading dye (Promega, Madison, WI, USA). Promega PCR
marker was loaded into a control lane at the manufacturer’s specifications (Promega).
Product bands were excised using the QIAquick® Gel Extraction Kit protocol according
to the manufacturer’s instructions (Qiagen). cDNA purity and concentration was
determined by standard 260nm:280nm spectrophotometric analysis using a Genesis
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10UV Spectronic Unicam (Spectronic Instruments). cDNA dilutions were performed
using ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen Corporation).
Southern Blot Analysis
Nucleic acid bands were transferred from the 2% agarose gel (described above)
to BioBond™ Plus Nylon Membrane (Sigma Chemical Co.) using the Alkaline Southern
Breeze™ Blotting Kit (Sigma Chemical Co.). The membrane was blocked overnight at
room temperature using a blocking solution of 1X Saline-Sodium Citrate (SSC), 1%
Bovine Serum Albumin (BSA) (Fisher Scientific, Pittsburgh, PA, USA), and 1% Sodium
Dodecyl Sulfate (SDS) (Sigma Chemical Co.). A one hour incubation at room
temperature was then performed using 20pmol biotinylated primary probe directed to
the TCRBC region (Integrated DNA Technologies, Inc.) per mL blocking buffer followed
by three five minute washings with a wash buffer of 1X SSC and 1% SDS (Sigma
Chemical Co.). A streptavidin-HRP conjugate (Amersham Biosciences, Piscataway, NJ,
USA) was added at a 1:5000 dilution in blocking buffer for 1 hour at room temperature.
Three final five-minute washes were performed using the wash buffer. The membrane
was developed using ECL™ detection reagents (Amersham Biosciences) according to
the manufacturer’s instructions. The membrane was then exposed to Biomax™ MR film
(Eastman Kodak Company, Rochester, NY, USA). The film was developed using a 100
Plus Automatic X-Ray Film Processor (All-Pro Imaging, Hicksville, NY, USA).

RESULTS
Primer Sequence Panel
The final TCRBV primer panel consists of fewer than 30 primers and one
TaqMan® probe. The amplification of the various alleles and subfamily members for a
given TCRBV family is diagrammed in Table I. As previously mentioned, each TCRBV
family can have multiple subfamily members, some with additional alleles. As described
by Arden, et al. 3, we have adhered to the accepted classification and nomenclature for
these families and their subfamily and allele members.
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Listed on the far left columns of Table 1 are the names of the primers and their
respective TCRBV families, whose subfamily and allele members are listed in the
adjacent column. A single primer was used for the amplification of a given TCRBV with
the following exceptions: two primers were needed to amplify all BV6 (B6JLB2 and
B6JLB3), BV12 (B12.1JLB and B12.2.3JLB), and BV13 (B13.1eJLB2 and B13.5JLB2)
members. There is no primer to amplify BV10 or BV19 as these families only contain
nonfunctional orphan or pseudogenes 3.
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B1H

primer
name(s)

TCR
family
B variable 1

B2Blum

B variable 2

B3H
B4H

B variable 3
B variable 4

B5JLB

B variable 5

B6JLB2/B6JLB3

B variable 6

B7JLB

B variable 7

B8JLB

B variable 8

B9H

B variable 9

B11H

B variable 11

B12.1JLB/B12.2.3JLB B variable 12

B13.1eJLB2/B13.5JLB2B variable 13

B14JLB2
B15H
B16H
B17Blum

B variable 14
B variable 15
B variable 16
B variable 17

B18JLB
B20JLB2

B variable 18
B variable 20

B21JLB

B variable 21

B22H

B variable 22

B23JLB2

B variable 23

B24H

B variable 24

B25JLB

B variable 25

CBJLB

B constant

TCRCB probe

B constant

TCR
TCR
GenBank
subfamily
sequence accession #
BV1S1A1
PL5.2
M13836
BV1S1A2
308C
M27904
BV2S1A1
PL2.13
M13840
BV2S1A2
WBDP25G
D13087
BV2S1A3
HT120
X57604
BV2S1A4
MT1-1
M11954
BV2S1A5
4.49
X74852
BV3S1
PL4.4
M13843
BV4S1A1
PL2.14
M13846
BV4S1A2
HBP48
X04926
BV4S1A3
PL5.7
M13847
BV5S1A1
PL7.16
M13849
BV5S1A2
ph24
M14271
BV5S2
IGRb09
X58802
BV5S3A1
HT415.9
X57611
BV5S3A2
HT415.3
X57612
BV5S3A3
IGRb08
X58801
BV5S4A1
IGRb06
X58803
BV5S4A2
AL62.24
M97709
BV5S6A1
HT415
X57615
BV5S6A2
IGRb07
X58804
BV5S6A3
AL61.270
M97707
X04934
BV6S1A1
HBP50
BV6S1A3
4D1
M13550
BV6S2A1
HBVT23
M27383
BV6S2A2
VB6.3
X61441
BV6S3A1
HBP25
X04931
BV6S4A1
IGRb10
X58805
BV6S4A2
WBDM28A
D13085
BV6S4A3
L17 beta
M13552
BV6S4A4
ph22
M14261
BV6S4A5
1.4
X74844
BV6S4A6
D38
L14854
BV6S5A1
ph16
M14262
BV6S5A2
GL-PA
X61443
BV6S6A1
HT147
X57607
BV6S6A2
VB6.14b
L14483
BV6S8A1
VB6.11a
L13762
BV6S8A2
VB6.11c
L14432
BV7S1A1
IGRB19
X58813
BV7S2A1
PL4.19
M13856
BV7S2A2
IGRb18
X58812
BV7S3A1
IGRb17
X58811
BV7S3A2
HT267.2
X57617
BV8S1
ph11
M14265
BV8S2A1
PL3.3
M13858
BV8S2A2
ph8
M14264
BV8S3
(lambda)VB8.3 X07223
BV9S1A1
HT307
X57614
BV9S1A2
VB9.n
L06889
BV11S1A1
PL3.12
M13861
BV11S1A2
1.3
X74845
BV12S1A1
PL4.2
M13862
BV12S2A1
IGRb13
X58808
BV12S2A2
H18.1
L26230
BV12S2A3
WBDM21C
D13084
BV12S3
HT96
X57609
BV13S1
PL4.24
M13863
BV13S2A1
VB13.2
X61445
BV13S3
IGRb14
X58809
BV13S4
VB13.4
X61447
BV13S5
IGRb15
X58810
BV13S6A1
IGRb16
X58815
BV13S6A2
HT165.2
X57606
BV13S6A3
3.1
X74848
BV13S6A4
VB13.n3
L06892
BV13S7
H127
L26228
BV14S1
PL8.1
M13865
BV15S1
ph32
M14269
BV16S1A1
HT370
X57723
BV17S1A1
HBVT02
M27388
BV17S1A2
S30.10
M97725
BV17S1A3
BV17S1
L19936
BV18S1
HBVT56
M27389
BV20S1A1
WBDM30A
D13086
BV20S1A3
HUT102beta
M13554
BV21S1
B17ct7
D16584
BV21S2A1
IGRb02
X58797
BV21S2A2
BV21.2
M33234
BV21S2A3
V beta 21
M62377
BV21S3A1
BV21.3
M33235
BV21S3A2
IGRb01
X58796
BV22S1A1
V beta 23
M62379
BV22S1A2
IGRb03
X58798
BV23S1A1
V beta 22
M62378
BV23S1A2
IGRb04
X58799
BV24S1A1
V beta 24
M62376
BV24S1A2
IGRb05
X58800
BV24S1A3
H130.1
U03115
BV25S1A1
HVB30.A
L26231
BV25S1A3
HsVB25
L26054
BC1
JM
K02885
BC2
L34740
BC1
JM
K02885
BC2
L34740

Table 1: TCRBV primer panel organization.
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The third column from the left in Table I, entitled TCR subfamily, contains all of
the subfamily (S) and alleles (A) for a given TCR family, per the previously described
nomenclature system 3. The final two columns of Table I, titled TCR sequence and
GenBank accession #, provide the reference sequences used in the development of our
primer sequences. When available, we have provided both the sequence clone name
as well as its listing in the GenBank database. Primer sequences are proprietary and
are available for licensing through the Institute for Scientific Research, Inc. (Fairmont,
WV)

Peripheral Blood Composition Analysis
The cellular composition of the peripheral blood from three healthy human
donors is presented in Table II. Cellular composition is as expected for healthy donors.
It was found that lymphocyte samples range from 30%-55% CD4+ T cells, 22%-44%
CD8+ T cells, and 4%-11% CD19+ B cells.

WBC
3
/uL)
(10
sample

neutrophils

eosinophils

basophils

monocytes

lymphocytes

A

3.73

57.00%

1.73%

0.69%

8.98%

31.60%

B

3.38

44.20%

8.08%

0.58%

6.51%

40.60%

C

5.09

57.40%

1.04%

0.79%

7.21%

33.60%

CD19+
CD4+
CD8+
4.11%
54.75%
21.65%
6.32%
29.62%
43.62%
10.61%
40.07%
25.16%

Table 2: Peripheral blood composition of donor samples.

All values are expressed as percent, except white blood cell (WBC) count, which is expressed as
thousand cells/microliter. Lymphocyte counts were further differentiated into percent CD19+, CD4+
and CD8+ as depicted in far right column.
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iCycler™ fluorescence signal corresponds to Southern Blot signal
Figure 1 depicts the fluorescence readings obtained on the iCycler™ using the
B1H/CBJLB primer set with the TCRCB TaqMan® probe. Fluorescence readings (RFU)
are reported here as the Ct value, or the cycle at which fluorescence readings exceeded
background fluorescence levels. Those samples with greater initial levels of target
template have fluorescence
levels that more quickly surpass
these

background

fluorescence

levels, or a lower Ct value, compared
to samples with less initial copies of
target template. The plus and minus
template samples are indicated in
Figure 1. The plus template sample
has a Ct value of 12 while the no
Figure 1: iCycler fluorescence readings during template sample has an expected
amplification of TCRBV1.

Ct value >34. Plus and minus

template samples were completed for all TCR variable family primers to ensure the
absence

of

autofluorescence

in

the

no

template

samples.

No

significant

autofluorescence levels were detected with the TCRBC TaqMan® probe and any of the
TCRBV primers.
In order to confirm the fluorescence readings obtained by the iCycler™, Southern
Blot analysis was performed on randomly chosen TCRBV PCR products. As exampled
by the B1H/CBJLB amplification product shown as the inset in Figure 1, the iCycler’s™
fluorescence readings are independently confirmed by Southern Blot analysis. Again,
the plus and minus template samples are labeled accordingly in the inset of Figure 1.
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Amplification Efficiency Determination
cDNA was diluted into 10 fold serial
dilutions and subjected to PCR amplification
to determine the degree of amplification
efficiency. Figure 2 depicts the fluorescence
levels seen with the amplification reaction
using the primer B6JLB2. The reaction using
this primer was ~93% efficient, results which Figure 2: Amplification efficiency analysis.
are typical for the other analyzed primer
sets. This amplification efficiency determination indicates that the PCR detection system
is sensitive in response to the amount of target template initially placed into the reaction
(refer to appendix for amplification efficiency calculation equation).

TCRV family gene expression as determined by real-time PCR
Figure 3 depicts the TCRBV expression profiles from three human peripheral blood
samples. Each data point is the mean of triplicate reactions with the standard error of
the mean indicated. One way Analysis of Variance with Tukey’s Post Hoc test was
performed for statistical analysis. Symbols indicate significant differences between the
three samples for a given primer. $$(P<0.001), #(P<0.01), and *(P<0.05). Significant
differences in expression levels were seen between samples A, B, and C for TCRBV8,
12, 15, 16, 17, 18, 20, 23, and 25. Both TCRBV mRNA and protein expression levels
(determined using the IOTest® Beta Mark TCR VB Repertoire Kit (Beckman Coulter))
demonstrated steady state expression levels (refer to appendix for method and data).
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Figure 3: Relative TCRBV mRNA expression levels of three human
peripheral blood samples based on Ct values

Figure 3: Relative TCRBV mRNA expression levels of three human peripheral blood samples based on Ct
values
(samples A, B, and C). $$ (P<0.001), # (P<0.01), * (P<0.05).
Note: A Ct difference of ~3.5 cycles was required to achieve 95% confidence, or p<0.05
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Figure 4 depicts the relative TCRBV1 expression profile, as determined by Ct
values, of a hematopoietic stem cell transplant patient prior to and following transplant.
The patient was a 54 year-old male being treated for chronic lymphocytic leukemia and
received peripheral blood hematopoietic stem cells from a matched related donor. The
patient had a staphylococcus infection, as well as graft-versus-host disease and
cytomegalovirus complications, immediately following transplant. These complications
resolved but the patient expired at week 14 post- transplant from graft-versus-host
disease complications. Significant changes in TCRBV1 expression were observed over
time between weeks –1 and 3, weeks 3 and 4, weeks 7 and 8, and weeks 8 and 9.

Figure 4:TCRBV1 expression level changes in a hematopoietic stem cell transplant recipient before and
after transplant.
Each data point is the mean of triplicate reactions with the standard error of the mean indicated. One
way Analysis of Variance with Bonferroni’s Multiple Comparison test was performed for statistical
analysis to monitor changes in the TCRBV1 expression from week-to-week. $$(P<0.001), #(P<0.01),
and *(P<0.05).
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DISCUSSION
Through the employment of primer panels previously developed

4-49

, many

investigators have examined the usage of the human TCR beta variable genes under
various biological conditions. Many of these reports, however, fall short of the desired
comprehensiveness to detect all TCRBV members. For example, due to the more
recent identification and classification of TCRBV families 21, 22, 23, 24, and 25, many
previous reports do not include analysis of some or all of these additional five families
17,20-30,32-39,41-43,45,46

4-

. Additionally many also would not amplify all subfamily and allele

members within a given TCRBV family. For example, based on sequence homology
analysis the panel proposed by Blumberg, et al., 7 will not amplify the subfamily member
BV8.3.
Others have tried different approaches to the amplification of all TCRBV
subfamily and allele members. For example, Lynas, et al.,

28

describe the use of single

primers to detect BV2/BV4 and BV18/BV8.3. Tsuruta, et al.,

44

have five separate

primers in their panel to amplify all members of the TCRBV5 family while we have been
able to identify a single primer sequence that we predict will amplify all 5 subfamilies
(including all 11 possible alleles). Therefore, a primer panel that will amplify all possible
alleles for the TCRBV families using as few primers as possible is a noteworthy
improvement in the area of T cell receptor gene expression analysis, as sample
availability is often a limiting factor.
While most of the previously cited primer panels we reviewed relied on
conventional PCR, followed by gel analysis and Southern Blotting or the inclusion of
labeled primers or nucleotides for sequence analysis there is at least one report of the
use of TCRBV primers in a SYBR green reaction

42

. While the paper by Sebille et al.,

yields to the same primer sequence concerns as many of the others, as it traces its
primer sequence roots back to the primers described by Genevee et al., 15 and Gorski et
al.,

17

, this does move the field of TCRBV gene expression analysis into the real-time

PCR arena. We have experimented with SYBR green reactions previously but prefer
the ease of analysis and additional sequence specificity offered by a TaqMan® probe.
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While our study focuses on the use of peripheral blood samples, there is nothing
intrinsic about our method that prevents using cells from other sources, for example cell
cultures, tissue samples, or synovial fluid. We have previously used silica membranebased extraction kits, such as GenElute™ Mammalian Total RNA Kit (Sigma Chemical
Co.), Rneasy® kit (Qiagen) and PAXgene™ Blood RNA kit (PreAnalytiX, Switzerland).
However, we chose to isolate RNA from our samples using phenol-chloroform
extraction, due to our success with improved yields compared to the silica membranebased technologies. While we chose to use the BioRad iCycler™ due to its availability
at our facilities, its larger sample capacity, and the permitted usage of conventional PCR
tubes, we have previously used the Roche Lightcycler®, demonstrating the flexibility of
platform usage but not validity that the primers provide equivalent results across all
platforms.
Consistent with previous reports

51-54

, differences in TCRBV expression levels do

exist between individuals and the level of those differences can change with time and
health of the individual. Our technology has not only been demonstrated functional by
the usage of sequence specific probes in real time PCR but has also been verified by
Southern Blot analysis and flow cytometry utilizing available TCRBV antibodies, with the
latter supporting the notion that the increased expression levels we observed with the
PCR system were due to the increased number of cells expressing such receptors as
opposed to only an increase in the amount of message in a given cell.
In terms of amplification efficiency, if a PCR reaction is 100% efficient, there will
theoretically be a decrease in the Ct value by one each time the template amount is
doubled (Roche Molecular Biochemicals, Technical Note No. LC 11/2000). Therefore,
for a 10-fold dilution, a difference of 3.25 cycles should be observed between each 10fold dilution. Our methodology is not only comprehensive but it is also efficient with a
typical amplification efficiency of ≥ 90%.
In conclusion, we have presented here a significant improvement to existing
technologies that enable one to detect all of the families, subfamilies, and alleles of the
TCRBV regions classified by Arden et al.,

3

using efficient, sequence specific real-time

PCR methodology. The user benefits from automated and integrated amplification,
detection, and analysis in a gel free environment with the choice of using various PCR
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platforms, sample sources, and sample processing methods. Additionally, this PCRbased method is approximately 25-fold less expensive than comparable flow cytometry
based methods. This technology can be applied to any area of study examining T cell
biology, including autoimmunity, transplantation, cancer therapy, and infectious disease.

55

REFERENCES

(1) von Boehmer H. The developmental biology of T lymphocytes. Annu Rev
Immunol. 1988;6:309-326.
(2) Saiki RK, Gelfand DH, Stoffel S et al. Primer-directed enzymatic amplification
of DNA with a thermostable DNA polymerase. Science. 1988;239:487-491.
(3) Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene
segment families. Immunogenetics. 1995;42:455-500.
(4) Abe J, Forrester J, Nakahara T et al. Selective stimulation of human T cells
with streptococcal erythrogenic toxins A and B. J Immunol. 1991;146:37473750.
(5) Abe J, Kotzin BL, Jujo K et al. Selective expansion of T cells expressing T-cell
receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc
Natl Acad Sci U S A. 1992;89:4066-4070.
(6) Ben Nun A, Liblau RS, Cohen L et al. Restricted T-cell receptor V beta gene
usage by myelin basic protein-specific T-cell clones in multiple sclerosis:
predominant genes vary in individuals. Proc Natl Acad Sci U S A.
1991;88:2466-2470.
(7) Blumberg RS, Yockey CE, Gross GG, Ebert EC, Balk SP. Human intestinal
intraepithelial lymphocytes are derived from a limited number of T cell clones
that utilize multiple V beta T cell receptor genes. J Immunol. 1993;150:51445153.
(8) Bragado R, Lauzurica P, Lopez D, Lopez de Castro JA. T cell receptor V beta
gene usage in a human alloreactive response. Shared structural features
among HLA-B27-specific T cell clones. J Exp Med. 1990;171:1189-1204.

56

(9) Choi YW, Kotzin B, Herron L et al. Interaction of Staphylococcus aureus toxin
"superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989;86:89418945.
(10) Dietrich PY, Caignard A, Diu A et al. Analysis of T-cell receptor variability in
transplanted

patients

with

acute

graft-versus-host

disease.

Blood.

1992;80:2419-2424.
(11) Dietrich PY, Caignard A, Lim A et al. In vivo T-cell clonal amplification at time
of acute graft-versus-host disease. Blood. 1994;84:2815-2820.
(12) Dombret H, Loiseau P, Bories JC, Sigaux F. Unexpected consistent
involvement of V beta gene segments in inappropriate T-cell receptor beta
gene rearrangements occurring in B-lineage acute lymphoblastic leukemias.
Blood. 1992;80:2614-2621.
(13) Even J, Lim A, Puisieux I et al. T-cell repertoires in healthy and diseased
human tissues analysed by T-cell receptor beta-chain CDR3 size
determination:

evidence

for

oligoclonal

expansions

in

tumours

and

inflammatory diseases. Res Immunol. 1995;146:65-80.
(14) Gagne K, Brouard S, Giral M et al. Highly altered V beta repertoire of T cells
infiltrating long-term rejected kidney allografts. J Immunol. 2000;164:15531563.
(15) Genevee C, Diu A, Nierat J et al. An experimentally validated panel of
subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for
the study of human T cell receptor variable V gene segment usage by
polymerase chain reaction. Eur J Immunol. 1992;22:1261-1269.
(16) Gorochov G, Debre P, Leblond V et al. Oligoclonal expansion of CD8+
CD57+ T cells with restricted T-cell receptor beta chain variability after bone
marrow transplantation. Blood. 1994;83:587-595.

57

(17) Gorski J, Yassai M, Zhu X et al. Circulating T cell repertoire complexity in
normal individuals and bone marrow recipients analyzed by CDR3 size
spectratyping. Correlation with immune status. J Immunol. 1994;152:51095119.
(18) Hirokawa M, Matsutani T, Horiuchi T et al. Extensive clonal expansion of T
lymphocytes causes contracted diversity of complementarity-determining
region 3 and skewed T cell receptor repertoires after allogeneic hematopoietic
cell transplantation. Bone Marrow Transplant. 2001;27:607-614.
(19) Hirokawa M, Matsutani T, Saitoh H et al. Distinct TCRAV and TCRBV
repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood
and GVHD lesions after human allogeneic bone marrow transplantation. Bone
Marrow Transplant. 2002;30:915-923.
(20) Ikeda H, Sato N, Matsuura A, Kikuchi K. Analysis of T-cell receptor V region
gene usage of cytotoxic T-lymphocytes and tumor-infiltrating lymphocytes
derived from human autologous gastric signet ring cell carcinomas. Cancer
Res. 1993;53:3078-3084.
(21) Kalams SA, Johnson RP, Trocha AK et al. Longitudinal analysis of T cell
receptor (TCR) gene usage by human immunodeficiency virus 1 envelopespecific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J Exp
Med. 1994;179:1261-1271.
(22) Kalams SA, Johnson RP, Dynan MJ et al. T cell receptor usage and fine
specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte
clones: analysis of quasispecies recognition reveals a dominant response
directed against a minor in vivo variant. J Exp Med. 1996;183:1669-1679.
(23) Kubo H, Abe J, Obata F et al. Dual recognition of a human cytotoxic T-cell
clone for melanoma antigens. Cancer Res. 1996;56:2368-2374.

58

(24) Kuijpers KC, van Dongen JJ, van der BP et al. A combined immunodeficiency
with oligoclonal CD8+, V beta 3-expressing, cytotoxic T lymphocytes in the
peripheral blood. J Immunol. 1992;149:3403-3410.
(25) Kusaka S, Grailer AP, Fechner JH, Jr. et al. Clonotype analysis of human
alloreactive T cells: a novel approach to studying peripheral tolerance in a
transplant recipient. J Immunol. 2000;164:2240-2247.
(26) Lang R, Pfeffer K, Wagner H, Heeg K. A rapid method for semiquantitative
analysis of the human V beta-repertoire using TaqManR PCR. J Immunol
Methods. 1997;203:181-192.
(27) Liu X, Chesnokova V, Forman SJ, Diamond DJ. Molecular analysis of T-cell
receptor repertoire in bone marrow transplant recipients: evidence for
oligoclonal T-cell expansion in graft-versus-host disease lesions. Blood.
1996;87:3032-3044.
(28) Lynas C, Howe D. Additional TCRV beta primers and minor method
modifications improve detection of clonal T-cell populations by RT-PCR. Mol
Pathol. 1997;50:53-55.
(29) Margolis DA, Casper JT, Segura AD et al. Infiltrating T cells during liver graftversus-host disease show a restricted T-cell repertoire. Biol Blood Marrow
Transplant. 2000;6:408-415.
(30) Maslanka K, Piatek T, Gorski J, Yassai M, Gorski J. Molecular analysis of T
cell repertoires. Spectratypes generated by multiplex polymerase chain
reaction and evaluated by radioactivity or fluorescence. Hum Immunol.
1995;44:28-34.
(31) Matsutani T, Yoshioka T, Tsuruta Y, Iwagami S, Suzuki R. Analysis of
TCRAV and TCRBV repertoires in healthy individuals by microplate
hybridization assay. Hum Immunol. 1997;56:57-69.

59

(32) Matsutani T, Yoshioka T, Tsuruta Y et al. Restricted usage of T-cell receptor
alpha-chain variable region (TCRAV) and T-cell receptor beta-chain variable
region

(TCRBV)

repertoires

after

human

allogeneic

haematopoietic

transplantation. Br J Haematol. 2000;109:759-769.
(33) McCarthy KP, Sloane JP, Kabarowski JH, Matutes E, Wiedemann LM. The
rapid detection of clonal T-cell proliferations in patients with lymphoid
disorders. Am J Pathol. 1991;138:821-828.
(34) Nuovo GJ, Morrison C, Porcu P, Caligiuri MA, Suster S. In situ determination
of T-cell receptor beta expression patterns. J Histochem Cytochem.
2001;49:139-145.
(35) Oaks MK, Downs JA, Tector AJ. T-cell receptor alpha and beta chain gene
expression in cells infiltrating human cardiac allografts. Am J Med Sci.
1995;309:26-34.
(36) Orsini E, Alyea EP, Schlossman R et al. Changes in T cell receptor repertoire
associated with graft-versus-tumor effect and graft-versus-host disease in
patients with relapsed multiple myeloma after donor lymphocyte infusion.
Bone Marrow Transplant. 2000;25:623-632.
(37) Panzara MA, Gussoni E, Steinman L, Oksenberg JR. Analysis of the T cell
repertoire using the PCR and specific oligonucleotide primers. Biotechniques.
1992;12:728-735.
(38) Pilch H, Hohn H, Freitag K et al. Improved assessment of T-cell receptor
(TCR) VB repertoire in clinical specimens: combination of TCR-CDR3
spectratyping with flow cytometry-based TCR VB frequency analysis. Clin
Diagn Lab Immunol. 2002;9:257-266.
(39) Puisieux I, Even J, Pannetier C et al. Oligoclonality of tumor-infiltrating
lymphocytes from human melanomas. J Immunol. 1994;153:2807-2818.

60

(40) Roers A, Montesinos-Rongen M, Hansmann ML, Rajewsky K, Kuppers R.
Amplification of TCRbeta gene rearrangements from micromanipulated single
cells: T cells rosetting around Hodgkin and Reed-Sternberg cells in Hodgkin's
disease are polyclonal. Eur J Immunol. 1998;28:2424-2431.
(41) Sarzotti M, Patel DD, Li X et al. T cell repertoire development in humans with
SCID after nonablative allogeneic marrow transplantation. J Immunol.
2003;170:2711-2718.
(42) Sebille F, Gagne K, Guillet M et al. Direct recognition of foreign MHC
determinants by naive T cells mobilizes specific Vbeta families without
skewing of the complementarity-determining region 3 length distribution. J
Immunol. 2001;167:3082-3088.
(43) Smith TJ, Terada N, Robinson CC, Gelfand EW. Acute infectious
mononucleosis stimulates the selective expression/expansion of V beta 6.1-3
and V beta 7 T cells. Blood. 1993;81:1521-1526.
(44) Tsuruta Y, Yoshioka T, Suzuki R, Sakata T. Analysis of the population of
human T cell receptor gamma and delta chain variable region subfamilies by
reverse dot blot hybridization. J Immunol Methods. 1994;169:17-23.
(45) Tsutsumi Y, Tanaka J, Sugita J et al. Analysis of T-cell repertoire and mixed
chimaerism in a patient with aplastic anaemia after allogeneic bone marrow
transplantation. Br J Haematol. 2002;118:136-139.
(46) Ueda D, Sato N, Matsuura A et al. T-cell receptor gene structures of HLAA26-restricted cytotoxic T lymphocyte lines against human autologous
pancreatic adenocarcinoma. Jpn J Cancer Res. 1995;86:691-697.
(47) Willenbrock K, Roers A, Blohbaum B, Rajewsky K, Hansmann ML. CD8(+) T
cells in Hodgkin's disease tumor tissue are a polyclonal population with
limited clonal expansion but little evidence of selection by antigen. Am J
Pathol. 2000;157:171-175.

61

(48) Wucherpfennig KW, Ota K, Endo N et al. Shared human T cell receptor V
beta usage to immunodominant regions of myelin basic protein. Science.
1990;248:1016-1019.
(49) Yoshioka T, Matsutani T, Iwagami S et al. Quantitative analysis of the usage
of human T cell receptor alpha and beta chain variable regions by reverse dot
blot hybridization. J Immunol Methods. 1997;201:145-155.
(50) Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. 'Touchdown' PCR to
circumvent spurious priming during gene amplification. Nucleic Acids Res.
1991;19:4008.
(51) Akolkar PN, Gulwani-Akolkar B, Pergolizzi R, Bigler RD, Silver J. Influence of
HLA genes on T cell receptor V segment frequencies and expression levels in
peripheral blood lymphocytes. J Immunol. 1993;150:2761-2773.
(52) DeBruyne LA, Lynch JP, III, Baker LA et al. Restricted V beta usage by T
cells infiltrating rejecting human lung allografts. J Immunol. 1996;156:34933500.
(53) Lima M, Teixeira MA, Queiros ML et al. Immunophenotype and TCR-Vbeta
repertoire of peripheral blood T-cells in acute infectious mononucleosis. Blood
Cells Mol Dis. 2003;30:1-12.
(54) Soroosh P, Shokri F, Azizi M, Jeddi-Tehrani M. Analysis of T-cell receptor
beta chain variable gene segment usage in healthy adult responders and
nonresponders to recombinant hepatitis B vaccine. Scand J Immunol.
2003;57:423-431.

62

THE PREVIOUS CHAPTER DESCRIBED THE DEVELOPMENT OF IMPROVED
TECHNOLOGY CAPABLE OF ACCURATELY AND EFFICIENTLY DETECTING
EXPRESSION OF ALL OF THE HUMAN TCRBV GENES.
THERE ARE MANY POTENTIAL APPLICATIONS OF SUCH TECHNOLOGY.
FOR MY PURPOSES, HOWEVER, I UTILIZED THE TECHNOLOGY TO DETERMINE
WHAT SPECIFIC T CELLS ARE ASSOCIATED WITH THE FOLLOWING SPECIFIC
EVENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION:

1)
2)
3)
4)

GRAFT-VERSUS-HOST DISEASE
CYTOMEGALOVIRUS REACTIVATION
IMMUNOSUPPRESSIVE THERAPIES (CYCLOSPORIN A AND TACROLIMUS)
ENGRAFTMENT OF THE TCRBV REPERTOIRE
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CHAPTER 3

SIMILARITY IN REPERTOIRE OF T CELLS ASSOCIATED WITH
OCCURRENCES OF CMV REACTIVATION AND GVHD POST HUMAN
HEMATOPOIETIC STEM CELL TRANSPLANTATION.
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ABSTRACT
Cytomegalovirus (CMV), after initial infection, typically remains in a latent state
and reactivates during periods of immune suppression, such as after allogeneic
hematopoietic stem cell (HSC) transplant. Prior studies have indicated a restricted
usage of specific TCRBV families directed against CMV antigens in otherwise healthy
individuals. We monitored, on a weekly basis, the usage of the T cell receptor beta
variable (TCRBV) repertoire in the peripheral blood of five HSC transplant recipients
using real-time RT-PCR and found that several TCRBV families (TCRBV 1-6, 11, 12.1,
13 (excluding 13.5), 15, 16, 20, 25) were significantly associated with CMV reactivation.
In addition, significant overlap exists in these families and those found to be associated
with graft-versus-host disease (GVHD), a common T cell mediated post transplant
complication. Our results may help to explain the common clinical association of CMV
reactivation and GVHD.

INTRODUCTION
Cytomegalovirus (CMV) is a human herpes virus that infects greater than 60% of
the world’s adult population1. While this virus typically presents itself as a latent
infection, it commonly reactivates during immuno-suppressed states, such as after
allogeneic hematopoietic stem cell transplant (HSCT) 2. Prior studies have indicated a
restricted usage of specific T cell receptor beta variable (TCRBV) families directed
against CMV antigens in otherwise healthy individuals

3-6

. We here examine the

expression of specific TCRBV families associated with CMV reactivation following
allogeneic hematopoietic stem cell (HSC) transplantation. In addition, we determined
that overlap exists in the TCRBV families associated with CMV reactivation and graftversus-host disease (GVHD), supporting previous reports of the clinical association of
GVHD and CMV reactivation

7-9

. GVHD is a common post transplant complication

where the donor-derived T cells attack and destroy the recipient’s tissue based upon
allogeneic disparities between the T cell receptor (TCR) and peptide:major
histocompatibility complex (p:MHC)

10

. In our study peripheral blood samples were

collected weekly from allogeneic HSC recipients through day 100 post-transplant. Donor
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and recipient peripheral blood samples were also collected prior to pre-transplant
conditioning therapies in order to serve as baseline reference samples. Despite the
complexities of the post transplant environment, we found that specific subsets of T
cells were significantly associated with CMV reactivation and that many of these same
TCRBV families were also associated with the development of GVHD in the patient
population studied.

MATERIALS AND METHODS
Patient population
Study subjects were patients undergoing allogeneic transplant treatment at West
Virginia University’s Blood and Marrow Transplant and Hematological Malignancy
Program, Morgantown, West Virginia (Table 1). Informed consent was obtained from
participants after the nature and possible consequences of the study had been fully
explained according to West Virginia University’s Institutional Review Board guidelines.
Prior to peripheral blood stem cell (PBSC) infusion, study recipients underwent
myeloblative conditioning regimens consisting of either Thiotepa (500 mg/m2 q12h x 2
doses), Campath-1H (20mg x 2 doses), and total body irradiation (TBI) (200 cGy x 5
fractions) or Busulfan (1mg/kg p.o. q6h x 16 doses) and Cytoxan (60 mg/kg/d x 2
doses). A 20 mL peripheral blood sample was collected weekly, via venipuncture from
hematopoietic

stem

cell

transplant

patients,

into

an

acid

citrate

dextrose

VACUTAINER™ blood collection tube (Becton Dickinson, Franklin Lakes, NJ, USA).
Buffy coat layers were isolated via centrifugation at 3300 rcf for 10 minutes.
Contaminating red blood cells were removed by hypotonic lysis.
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recipient

sex

age

disease

donor
MRD

pretreatment
regimen
TT/TBI/Campath

CMV status
recipient/donor
neg/neg

1

M

54

AML

2

M

54

CLL

MRD

TT/TBI/Campath

pos/neg

3

M

51

NHL

MRD

TT/TBI/Campath

pos/neg

4

F

41

CML

MRD

TT/TBI/Campath

neg/neg

5

F

41

CML

MUD

Bu/Cy2

pos/pos

post tranplant
complications
GVHD grade I
bacterial pneumonia
viral mouth sores
staphylococcus infection
bacterial URI/sinusitis
GVHD grades II and IV
CMV reactivation
staphylococcus infection
GVHD grade II
CMV reactivation
staphylococcus infection
GVHD grade III
C. difficile
viral mouth sores
Enterococcus faecalis
GVHD grade II
CMV reactivation
bacterial gastritis
Cornybacter diptheroid

Table 1: Patient demographics
All patients received peripheral blood hematopoietic stem cell transplants from an HLA-matched related
donor (MRD) with the exception of recipient 5, who received stem cells from an HLA-matched unrelated
donor (MUD). HLA matching was performed serologically for all MRD but was determined using
molecular typing for MUD. Cytomegalovirus (CMV) status was determined in both recipient and donor
prior to transplant by evaluating CMV IgG and IgM serum levels. CMV reactivation was monitored weekly
by antigenemia testing for recipients at risk for CMV reactivation (donor and/or recipient with prior history
of CMV exposure). Complications experienced in the recipient post transplant, as determined by standard
clinical evaluation, are indicated on the far right side of the table. All patients were living at the conclusion
of our study. Abbreviations: M, male; F, female; AML, acute myelogenous leukemia; CLL, chronic
lymphocytic leukemia; NHL, non-Hodgkin lymphoma; CML, chronic myelogenous leukemia; TT, Thiotepa;
TBI, total body irradiation; Bu, Busulfan; Cy2, Cytoxan; GVHD, graft-versus-host disease.
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Donors
All donors were serologically HLA matched to the recipient at a minimum of HLAA, B, and DR loci. The patient undergoing an unrelated donor transplants was also
molecularly matched at the allele level. PBSC donors were mobilized with filgrastim (GCSF) at 10ug/kg/day for 5 days with stem cell collection occurring on day 5. The
number of PBSC collected was 3-5 x 106 HSC/kg of recipient body weight.

GVHD Prophylaxis and Supportive Care
Cyclosporin A (CSA) or tacrolimus (FK506) treatment started one day before
transplant (d-1) as part of standard graft-versus-host disease prophylaxis and continued
throughout the study period. The patients also received pulse methotrexate as part of
GVHD prophylaxis. Patients were monitored bi-weekly for CSA and FK506 serum
concentrations, with dosages adjusted as necessary to be within the preferred protocol
serum concentrations of 200+/-20 ng/mL for CSA and 7-12 ng/mL for FK506. Additional
supportive care, including anti-fungal, anti-viral, and anti-PCP prophylaxis were
provided according to standard operating policies. CMV reactivation was monitored
weekly by antigenemia testing (ViroMed Laboratories, Inc., Minnetonka, MN).

RNA Isolation
Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent
according to the manufacturer’s directions (Ambion, Austin, TX, USA). RNA was
dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA
according to the manufacturer’s recommendations using DNA-free™ (Ambion, Austin,
TX, USA). RNA purity and concentration was determined by standard 260nm:280nm
spectrophotometric analysis using a Genesis 10UV Spectronic Unicam (Spectronic
Instruments, Rochester, NY, USA).
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RT-PCR
One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit
(Qiagen, Valencia, CA, USA). Recommended reaction mixtures were scaled down to a
total reaction volume of 20 µL using 0.04 µg RNA with the following primer and probe
concentrations: 0.4 µM TCRBV primer (Biosource International, Camarillo, CA, USA),
0.4 µM TCRBC primer (Biosource International, Camarillo, CA, USA), and 0.2 µM
TCRBC TaqMan® probe, 5’ 6-FAM, 3’ BHQ™-1 (Integrated DNA Technologies, Inc.,
Coralville, IA, USA). 18SrRNA control reactions were performed in parallel using 0.4 µM
each of sense and anti-sense primers (Biosource International, Camarillo, CA, USA)
and 0.2 µM 18SrRNA TaqMan® probe, 5’ 6-FAM, 3’ BHQ™-1 (Integrated DNA
Technologies, Inc., Coralville, IA, USA). Primer and probe sequences were previously
described (Brewer and Ericson, J. of Immunol. Methods, in press). An iCycler™
(BioRad Laboratories, Hercules, CA, USA) was used for the RT and amplification
cycles. RT was performed at 50oC for 60 minutes, max ramp speed, followed by an
initial Taq activation step of 15 minutes at 95oC, max ramp speed. A TouchDown PCR
approach

11

was used with the following cycling conditions: denaturation for 15 seconds

at 95oC, max ramp speed, annealing for 30 seconds starting at 70oC decreasing by 2oC
for 10 repeats, max ramp speed, and extension for 40 seconds at 72oC, min ramp
speed. After this TouchDown of the annealing temperature, 50 cycles were performed
as follows with the optical data collection occurring at the extension step: 15 seconds at
95oC (max ramp speed), 30 seconds at 52oC (max ramp speed), and 40 seconds at
60oC (min ramp speed). Reactions were held at 4oC upon the conclusion of the run.

Statistical Analyses
One-way analysis of variance with Bonferroni’s Multiple Comparison Test was
used to determine the TCRBV families associated with GVHD and CMV reactivation.
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RESULTS
Increased expression of specific TCRBV families is associated with reactivation
of cytomegalovirus post peripheral blood hematopoietic stem cell transplant.
Using serial time points, we analyzed the alterations in TCRBV expression over
time to determine which TCRBV families were associated with CMV reactivation
compared to periods without CMV reactivation. All patients in our study were
determined to be 100% donor engrafted at day 30 post-transplant, with the exception of
recipient 5, whose chimerism analysis was not performed until day 100 post transplant,
at which point chimerism was also determined to be 100% donor in origin. We found an
increase in the expression of TCRBV families 1-6, 11, 12.1, 13 (excluding 13.5), 15, 16,
20, and 25 with CMV reactivation compared to sampling periods in which CMV
antigenemia was not detected (Table 2).

Increased expression of specific TCRBV families is associated with Graft-versusHost Disease post peripheral blood hematopoietic stem cell transplant and has
significant similarity to those families linked to CMV reactivation.
In addition to investigating the increased expression of specific TCRBV families
in the setting of CMV reactivation, we also examined the expression profiles of TCRBV
families associated with GVHD post HSC transplant. By weekly monitoring of the T cell
repertoire, in addition to baseline sampling, we were able to circumvent some of the
concerns associated with previous GVHD reports, such as the lack of baseline samples
and serial time point analyses

12-17

. All five of our patients developed acute GVHD post

HSCT, primarily grades I-II (Table 1). When we examined the TCRBV expression profile
during periods when patients had GVHD and compared this to periods without GVHD,
we found significant increases in the expression of TCRBV 1-6, 12.1, 13 (excluding
13.5), and 16, associated with GVHD grades I-II, with an additional increase in TCRBV
18 seen in a patient with GVHD grade IV (Table 2).
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TCRBV increases associated with
CMV reactivation
1
2
3
4
5
6
11
12.1
13 (excluding 13.5)
15
16

TCRBV increases associated with
GVHD grade I/II
1
2
3
4
5
6
12.1
13 (excluding 13.5)
16
*18

20
25
Table 2: Increased expression of specific families of TCRBV is associated with cytomegalovirus (CMV)
reactivation and Graft-versus-Host Disease (GVHD) post peripheral blood stem cell transplant.
Specific TCRBV families were significantly increased (p<0.05) with the occurrence of CMV reactivation,
compared to periods in which CMV antigenemia was not detected and also with the occurrence of GVHD
grades I and II, compared to periods without GVHD complications. *In a patient with grade IV GVHD an
increase in TCRBV18 was seen in addition to the increase in TCRBV families seen in GVHD grades I-II.

DISCUSSION
A number of studies have examined the role of specific T cells in the immune
response to CMV antigens. While a previous study looking at the TCRBV expression
during CMV reactivation in kidney and liver transplants found no preference for TCRBV
usage

18

, we found great similarity in our results and those examining the TCRBV

expression of CMV reactive T cells found in otherwise healthy individuals

3-6

. For

example, studies using CMV reactive T cell from healthy donors expressed TCRBV
families 2 and 20 6, TCRBV families 3, 6.7, 13.1, and 20 5, and TCRBV families 1, 2,
5.1, 12, 13.1, and 16 3. Many of these previous studies utilized tetramer technology to
remove CMV reactive T cells, which were then analyzed for TCRBV expression via
antibody staining and flow cytometry. The greatest limitation of previously described
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studies is that antibodies were not available to all of the TCRBV families, such as
TCRBV 4, 11, 13, 15, and sometimes 25. We suspect that the reason we detected the
expression of additional TCRBV families with CMV reactivation compared to these
previous studies was that we used a primer panel that could detect all of the TCRBV
families and their alleles.
Similarly a number of reports have described the association of specific TCRBV
families with GVHD, with some of these studies not only examining peripheral blood
samples but also GVHD tissue lesions

12-17,19-25

. Many of these studies, however,

contained very limited numbers of sampling points; for example some studies primarily
evaluated samples upon the diagnosis of GVHD and others did not contain baseline
sampling

12-17

. In this aspect, our study significantly adds to the investigation of immune

response after hematopoietic stem cell (HSC) transplantation by providing serial time
point analyses using a comprehensive primer panel, which can detect all TCRBV
families and alleles.
Several reports have detailed the clinical association of GVHD and CMV
reactivation

7-9

. Larsson et al., observed a decreased risk for the development of GVHD

when patients were preemptively treated with anti-viral therapy

7,8

while Vassallo et al.,

observed an association between skin GVHD and the presence of CMV antigens in the
patient’s peripheral blood 9. A recently published study noted cross reactivity of an HLADR7 restricted CMV-specific T cell for an HLA-DR4 allo-antigen 7. This could possibly
account for the overlap we saw in TCRBV families associated with both GVHD and
CMV reactivation.
In conclusion, the developing immune system found in hematopoietic stem cell
transplant patients responds to CMV antigen exposure with the alteration of the TCRBV
profile with great similarity to that described in prior non-transplant related reports.
Additionally, great similarities exist in the alterations of the TCRBV profile associated
with CMV reactivation and the occurrence of GVHD, supporting prior reports of such a
clinical association.
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CHAPTER 4

ENGRAFTMENT OF T CELL RECEPTOR (TCR) REPERTOIRE IN
MYELOABLATED ALLOGENEIC HEMATOPOIETIC STEM CELL
RECIPIENTS MIMICS DONOR TCR REPERTOIRE.
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ABSTRACT
Hematopoietic stem cell (HSC) transplantation is used to rescue the immune
system in patients who have received myeloblative regimens targeted at eradication of
various hematological malignancies. In allogeneic HSC transplantation, stem cells from
a healthy donor are infused into the recipient with the intent of reconstituting the
recipient’s immune system. Using the most comprehensive set of TCRBV primers
available, we determined through real time RT-PCR that the reconstitution of the
recipient’s T cell repertoire post- hematopoietic stem cell transplant was of a higher
correlation to that found in the donor compared to that found in the recipient prior to
transplant. Our results argue that, despite the influence of the recipient’s environment,
the donor stem cells mature in the recipient’s body with a TCRBV repertoire reminiscent
of that found in the donor.
INTRODUCTION
The major goal of allogeneic hematopoietic stem cell transplantation is to achieve
complete engraftment of healthy donor hematopoietic stem cells and subsequent
immune reconstitution within the new environment of the recipient. T cells are a critical
component of the recipient’s defense system against invading pathogens and the
reactivation of latent infections through the recognition of antigen through the T cell
receptor (TCR). While T cells play a critical role in the immune system’s defenses, it is
not known whether the maturing T cells found in the recipient display a T cell receptor
beta variable (TCRBV) repertoire more like that in the donor or if they exhibit a
repertoire more reminiscent of that found in the recipient prior to transplant. In this
study, we used real-time RT-PCR and a comprehensive panel of primers, developed in
response to the reclassification of the TCR genes 1, to monitor the profile of the
engrafting TCRBV regions. In the first 100 days after transplant, despite the influence of
the recipient’s HSC environment on the development of the immature cells 2-4, the T cell
repertoire appears to develop with a phenotype more reminiscent of that found in the
donor as opposed to that found in the recipient prior to transplant.
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MATERIALS AND METHODS
Patient population
Study subjects (n=4) were patients undergoing transplant treatment at West
Virginia University’s Blood and Marrow Transplant and Hematological Malignancy
Program, Morgantown, West Virginia. Informed consent was obtained from participants
after the nature and possible consequences of the study had been fully explained
according to West Virginia University’s Institutional Review Board guidelines. All study
patients received hematopoietic stem cells collected from the peripheral blood of
mobilized donors who had been primed with G-CSF. The donors were serologically HLA
matched to the recipient at a minimum of HLA-A, B, and DR loci. Prior to peripheral
blood stem cell (PBSC) infusion, study recipients underwent myeloblative conditioning
regimens consisting of either Thiotepa (500 mg/m2 q12h x 2 doses), Campath-1H
(20mg x 2 doses), and total body irradiation (TBI) (1000 cGy total dose: given in 200cGy
fractions) or Busulfan (1mg/kg p.o. q6h x 16 doses) and Cytoxan (60 mg/kg/d x 2
doses) (Table 1). Full supportive care, including GVHD prophylaxis, anti-fungal, antiviral, and anti-PCP prophylaxis, empiric anti-microbial therapy for neutropenic febrile
episodes, and transfusions were provided per standard operating policies. Peripheral
blood, ~20 mL, was collected weekly, via venipuncture from hematopoietic stem cell
transplant patients, into an acid citrate dextrose VACUTAINER™ blood collection tube
(Becton Dickinson, Franklin Lakes, NJ, USA). Buffy coat layers were isolated via
centrifugation at 3300 rcf for 10 minutes. Contaminating red blood cells were removed
by hypotonic lysis.
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recipient

sex

age

disease

donor

1

M

54

AML

MRD

pretreatment
regimen
TT/TBI/Campath

2

M

54

CLL

MRD

TT/TBI/Campath

3

M

51

NHL

MRD

4

F

41

CML

MUD

immunosuppressive
therapy
CSA

CSA
except for w+12
when switched to FK506
to treat GVHD IV
TT/TBI/Campath
CSA

Bu/Cy2

CSA

CMV status
recipient/donor
neg/neg

pos/neg

pos/neg

pos/pos

Table 1: Patient demographics
All patients received peripheral blood hematopoietic stem cell transplants from an HLA-matched related
donor (MRD). HLA matching was performed serologically. Cytomegalovirus (CMV) status was determined
in both recipient and donor prior to transplant by evaluating CMV IgG and IgM serum levels. Complications
experienced in the recipient post transplant, as determined by standard clinical evaluation, are indicated on
the far right side of the table. All patients were living at the conclusion of our study. Abbreviations: M, male;
F, female; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin
lymphoma; CML, chronic myelogenous leukemia; TT, Thiotepa; TBI, total body irradiation; Bu, Busulfan;
Cy2, Cytoxan; GVHD, graft-versus-host disease.

RNA Isolation
Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent
as previously described (Brewer and Ericson, J. of Immunol. Methods, in press). RNA
was dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA
according to the manufacturer’s recommendations using DNA-free™ (Ambion, Austin,
TX, USA). RNA purity and concentration was determined by standard 260nm:280nm
spectrophotometric analysis using a Genesis 10UV Spectronic Unicam (Spectronic
Instruments, Rochester, NY, USA).
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RT-PCR
One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit
(Qiagen, Valencia, CA, USA) with sequence specific detection as previously described
(Brewer and Ericson, J. of Immunol. Methods, in press).

Statistical Analyses
Spearman rank correlation coefficient analysis was used to determine the
correlation of the TCRBV engraftment phenotypes.

RESULTS AND DISCUSSION
The TCRBV repertoire engrafts with a phenotype similar to that present in the
donor.
By analyzing the expression of all of the TCRBV families in the donor and
recipient pre-transplant followed by weekly analysis of these families in the recipient
post transplant, we could monitor the TCRBV phenotype of the recipient’s engrafted
cells during the early reconstitution period (Table 2). While neutrophil engraftment
begins one to two weeks after transplant, complete restoration of the CD3+ population
typically requires many months post-transplant 5. We compared correlation parameters
at weekly intervals and here report the correlation seen at baseline and at day 100. The
day 100 TCRBV expression patterns obtained from patients 1, 2, and 3 showed a
stronger correlation to the baseline donor TCRBV expression profile compared to the
recipient’s baseline TCRBV repertoires (sample 1: -0.193 vs. 0.68, sample 2: 0.330 vs.
0.510, sample 3: 0.329 vs. 0.664). At the conclusion of this study, there was a
decreased correlation of recipient samples to their own pre-transplant TCRBV profile
when compared to the donor’s baseline TCRBV expression profile (sample 1: -0.219 vs.
0.68, sample 2: 0.289 vs. 0.510, sample 3: 0.537 vs. 0.664). These results were
compared to the correlation of the TCRBV repertoire found in healthy peripheral blood
donors over a period of two weeks, which exhibited a correlation to self of ~0.75 (Table
2).
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sample
recipient 1
recipient 2
recipient 3
recipient 4

correlation to self
t =0 (baseline)
1
1
1
1

correlation to donor
t =0 (baseline)
-0.192820513
0.33025641
0.329230769
0.517264957

healthy volunteer
donors
donor 1
donor 2
donor 3
donor 4

correlation to self
t =0 (baseline)
1
1
1
1

correlation to self
t =+2 weeks
0.748462
0.756154
0.789231
0.742692

correlation to self
t =d+100
-0.218803419
0.289230769
0.536752137
0.361367521

correlation to donor
t =d+100
0.68
0.51042735
0.663931624
0.246495726

Table 2: The TCRBV repertoire engrafts with a phenotype similar to that present in the donor.
Spearman rank correlation coefficients were determined for the TCRBV repertoire expression
in both recipient and donor prior to transplant (baseline) and at the conclusion of the study
(day +100). A correlation coefficient of one represents a perfect correlation. All recipients,
with the exception of recipient 4, had a greater correlation to the donor than to themselves at
day +100. This is compared in the context of the TCRBV repertoire observed in healthy
individuals over a two-week period.

With a single exception, recipient 4, we observed the engraftment of a T cell
receptor phenotype with greater correlation to baseline profiles found in the donors, as
opposed to those found in the recipients, prior to transplant. Recipient number 4 was
the only patient in our study who received a different pre-conditioning regimen, Cytoxan
and Busulfan, compared to the TT/TBI/Campath-1H regimen. One possible explanation
for this difference is the highly T-cell suppressive effect observed in patients who
receive a preparative regimen containing Campath-1H (anti-CD52), an agents whose
effects linger due to its persistence in patient serum several weeks after its final
administration.
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All patients were determined to be 100% donor engrafted at day 30 posttransplant, with the exception of recipient 4, whose chimerism analysis was not
performed until day 100 post transplant, at which point chimerism was also determined
to be 100% donor in origin. While these results are preliminary, they suggest that the
developing TCRBV repertoire in the recipient is more closely reflecting that found in the
donor as opposed to that found in the recipient prior to transplant. It is unlikely that
these results are attributable to mature donor T cells found within the graft as recipients
received Campath therapy (anti-CD52), which targets T cells for antibody dependent
lysis 6 and samples also exhibited the formation of TRECs.
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CHAPTER 5

CYCLOSPORINE A (CSA) AND TACROLIMUS (FK506)
DIFFERENTIALLY ALTER T CELL RECEPTOR (TCR) EXPRESSION
IN VIVO.
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ABSTRACT
Cyclosporin

A

(CSA)

and

tacrolimus

(FK506)

are

two

common

immunosuppressive agents used post blood and marrow transplantation. They exert
their effects through the inhibition of calcineurin activity and subsequent inhibition of IL-2
production. IL-2 is a cytokine needed for proliferation of activated T cells, an immune
cell commonly responsible for post transplant complications such as graft rejection and
graft-versus-host disease. Despite similarity in their mode of action, we observed
polarized effects of CSA and FK506 on the human T cell repertoire, as monitored
through the expression of the T cell receptor beta variable (TCRBV) regions. To
determine the possible mechanism for this difference, in vitro experiments using the
Jurkat human T-cell line were performed. The effects of CSA and FK506 on cell
viability, cell proliferation, IL-2 production, and calcineurin inhibition were determined
and no significant differences between the two agents were observed. The data suggest
that a secondary mechanism of action exists for the different TCRBV repertoire induced
by exposure to CSA and FK506.
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INTRODUCTION
Immunosuppressive agents are widely used in the treatment of various medical
conditions, in particular for allogeneic blood and marrow transplantation (BMT). Post
transplant recipients are at a significant risk of rejecting their graft or developing a
condition known as graft-versus-host disease (GVHD). T lymphocytes are known to be
the primary immune mediators of such reactions

1,1-5

. Cyclosporin A (CSA) and

tacrolimus (FK506) are two commonly employed agents used to prevent allograft
rejection and to decrease the risk of developing GVHD in the BMT setting 6.

Figure 1: Abbreviated schematic of the signaling pathway activated by engagement of the T cell receptor
(TCR) and its inhibition by CSA and FK506.

Abbreviations: p:MHC, peptide:major histocompatibility complex; TCR, T cell receptor; ITAMS,
immunoreceptor tyrosine-based activation motifs; PLC, phospholipase C; PIP-2, phosphatidylinositol
biphosphate; IP3, inositol triphosphate; DAG, diacylglycerol; Ca2+, calcium; CaM, calmodulin; PKC,
protein kinase C; CSA, cyclosporin A; FKBP, FK-binding protein; NFAT, nuclear factor of activated T
cells; NFκB, nuclear factor κB; IL2, interleukin 2.
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The overall effect of CSA and FK506 is to impair the production of interleukin 2
(IL-2) by T lymphocytes. This is accomplished through the binding of CSA and FK506 to
cyclophilin

7,8

and FK506-binding proteins

9-12

, respectively. This binding causes the

subsequent inhibition of the protein calcineurin, a protein critical to the production of IL2 (Figure 1) 13-16. IL-2 is produced primarily by activated T cells and is required for T cell
proliferation

17

. Since extensive similarities (including mechanism of action and agent

entry into cells) exist between CSA and its derivative, FK506

18

, suppression of the T

lymphocyte response is expected to be comprehensive and similar between the two
agents. However, we observed polarized effects of CSA and FK506 on the T cell
repertoire, as monitored through T cell receptor beta variable region (TCRBV)
expression patterns. FK506 suppressed the expression of the majority of TCRBV
families while an increased expression in specific TCRBV families was observed with
CSA. Cell viability, proliferation, IL-2 production, and calcineurin activity in response to
CSA and FK506 treatments were measured in vitro using the Jurkat human T-cell line.
In addition to their extensive usage as an in vitro human T cell model, Jurkat cells were
selected based upon their expression of TCRBV8

19

, a TCR that showed varied

responses to CSA and FK506 in our experiments. The experiments were designed to
determine the potential mechanistic difference that could be responsible for the differing
TCRBV expression pattern observed in vivo.
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MATERIALS AND METHODS
Human Subjects
Study subjects (n=5) were patients who underwent allogeneic peripheral blood
stem cell transplants at West Virginia University’s Mary Babb Randolph Cancer Center,
Morgantown, West Virginia. Informed consent was obtained from participants after the
nature and possible consequences of the study had been fully explained according to
West Virginia University’s Internal Review Board guidelines. A volume of ~20 mL
peripheral blood was collected weekly through day 100 post transplant, via venipuncture
from hematopoietic stem cell transplant patients, into an acid citrate dextrose
VACUTAINER™ blood collection tube (Becton Dickinson, Franklin Lakes, NJ, USA).
Buffy coat layers were isolated via centrifugation at 3300 rcf for 10 minutes.
Contaminating red blood cells were removed by hypotonic lysis.
Cell Lines
In vitro experiments were performed using the Jurkat human T-cell line (clone
E6-1) (American Type Culture Collection, Rockville, MD). Cells were cultured at a
density of 4x105 cells/mL in RPMI-1640 (HyClone, Logan, UT) supplemented with 10%
heat-inactivated fetal calf serum (FCS) (Hyclone), 2 mM L-glutamine (BioWhittaker,
Walkersville, MD), penicillin (100U/mL) (BioWhittaker), streptomycin (100ug/mL)
(BioWhittaker), and 2-mercaptoethanol (0.049 mM) (Sigma Chemical Co., St. Louis,
MO), and 50 mM Hepes (BioWhittaker).
Treatments
For human studies, patients were treated with CSA and/or FK506 according to
established treatment protocols at the West Virginia University Mary Babb Randolph
Cancer Center’s Blood and Marrow Transplant Program. CSA therapy is classically
utilized when the recipient has a matched related donor (MRD) and FK506 therapy is
instituted when the recipient has a matched unrelated donor (MUD) or is unresponsive
post-transplant to CSA therapy. CSA and/or FK506 treatment started one day before
transplant (d-1) and continued throughout the study period. Patients were monitored biweekly for CSA and FK506 serum concentrations. Patient dosages were adjusted, as
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necessary, to be within the preferred protocol serum concentrations of 200+/-20 ng/mL
for CSA and 7-12 ng/mL for FK506.
For in vitro cell culture studies, CSA (Bedford Laboratories, Bedford, OH) and
FK506 (Fujisawa Healthcare, Inc., Deerfield, IL) were diluted in prepared media
(previously described) to obtain 1/2x , 1x, and 2x of the target therapeutic dose. This
resulted in the following concentrations: for CSA, 100ng/mL, 200ng/mL, and 400ng/mL;
for FK506, 5ng/mL, 10ng/mL, and 20ng/mL. Cells were pretreated +/- CSA or FK506 for
30 minutes at 37oC followed by addition of the stimulating agents phorbol 12-myristate
acetate (PMA) (Sigma Chemical Co.) and A23187 calcium ionophore (Sigma Chemical
Co.) at 10ng/mL and 1 ug/mL, respectively.

RNA Isolation
Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent
according to the manufacturer’s directions (Ambion, Austin, TX, USA). RNA was
dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA
according to the manufacturer’s recommendations using DNA-free™ (Ambion). RNA
purity and concentration was determined by standard 260nm:280nm spectrophotometric
analysis using a Genesis 10UV Spectronic Unicam (Spectronic Instruments, Rochester,
NY, USA).
RT-PCR
One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit
(Qiagen, Valencia, CA, USA). Recommended reaction mixtures were scaled down to a
total reaction volume of 20 µL using 0.04 µg RNA with the following primer and probe
concentrations: 0.4 µM TCRBV primer (Biosource International, Camarillo, CA, USA),
0.4 µM TCRBC primer (Biosource International), and 0.2 µM TCRBC TaqMan® probe, 5’
6-FAM, 3’ BHQ™-1 (Integrated DNA Technologies, Inc., Coralville, IA, USA). The
method, including primer and probe sequences, was as previously described (Brewer
and Ericson, J. Immunol. Method, in press). In brief, 18SrRNA standardization reactions
were performed in parallel using 0.4 µM each of sense and anti-sense primers
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(Biosource International) and 0.2 µM 18S rRNA TaqMan® probe, 5’ 6-FAM, 3’ BHQ™1 (Integrated DNA Technologies, Inc.). An iCycler™ (BioRad Laboratories, Hercules,
CA, USA) was used for the RT and amplification cycles. RT was performed at 50oC for
60 minutes, max ramp speed, followed by an initial Taq activation step of 15 minutes at
95oC, max ramp speed. A TouchDown PCR approach

20

was used with the following

cycling conditions: denaturation for 15 seconds at 95oC, max ramp speed, annealing for
30 seconds starting at 70oC decreasing by 2oC for 10 repeats, max ramp speed, and
extension for 40 seconds at 72oC, min ramp speed. After this TouchDown of the
annealing temperature, 50 cycles were performed as follows with the optical data
collection occurring at the extension step: 15 seconds at 95oC (max ramp speed), 30
seconds at 52oC (max ramp speed), and 40 seconds at 60oC (min ramp speed).
Reactions were held at 4oC upon the conclusion of the run. Cycle threshold (Ct) values,
or the cycle at which fluorescent amplification readings exceed background level, were
determined using iCycler™ iQ Optical System Software Version 3.0a (BioRad
Laboratories, Hercules, CA, USA). The primer sets utilized in this study have been
previously shown to yield Ct values that are directly proportional to the amount of
template present in the initial reactions (Brewer and Ericson, J. Immunol. Method, in
press).
Viability assay
3x106 Jurkat cells (at a density of 4x105 cells/mL) were plated per treatment
condition. At time points 24 hours, 36 hours, and 48 hours, 1x106 cells were removed
from the culture. Viability was determined by trypan blue exclusion (Gibco Laboratories,
Grand Island, NY) and 7-AAD incorporation (BD Pharmingen, San Diego, CA). 7-AAD
incorporation was performed according to the manufacturer’s instructions. Stained cells
were resuspended in 200 µL 1% paraformaldehyde solution. 30,000 total events were
collected per sample using a Becton Dickinson FACSCalibur™ that was calibrated using
Calibrite Beads™ and FACSCOMP™ software (Becton Dickinson, Franklin Lakes, NJ).
Acquisition of data was performed using CellQuest™ Pro software (Becton Dickinson).
Data was analyzed using Windows Multiple Document Interface (WinMDI) version 2.8
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(Joseph Trotter, The Scripps Research Institute, http://facs.scripps.edu/software.html
[14 December 2001]).
Cell proliferation assay
Cell proliferation was monitored by labeling cells prior to culture using the
Molecular Probes Vybrant™ CFDA SE Cell Tracer Kit (Molecular Probes, Inc., Eugene,
OR) according to manufacturer’s instructions. 3x106 CFSE labeled Jurkat cells (at a
density of 4x105 cells/mL) were plated per treatment condition. At time points, 24 hours,
36 hours, and 48 hours, 1x106 cells were removed from the culture, spun down and
washed in 1x PBS prior to being resuspend in 200uL 1% paraformaldehyde. Cells were
analyzed using a Becton Dickinson FACSCalibur™ that was calibrated using Calibrite
Beads™ and FACSCOMP™ software (Becton Dickinson). Acquisition of data was
performed using CellQuest™ Pro software (Becton Dickinson). Results were analyzed
using ModFit LT™ software (Verity Software House, Topsham, ME). A total of 30,000
events were collected and analyzed per sample.
IL-2 production
3x106 Jurkat cells (at a density of 4x105 cells/mL) were plated per treatment
condition. At time points, 24 hours, 36 hours, and 48 hours, 1x106 cells were removed
from the culture and spun down. Supernatant was harvested and used to determine IL-2
production using the BD OptEIA™ Human IL-2 ELISA Kit II (BD Biosciences, San Diego,
CA) according to manufacturer’s instructions. Colorimetric reactions were read on a
Labsystems Multiskan MCC/340 microplate reader (Molecular Devices Corporation,
Sunnyvale, CA) and data was analyzed using the Genesis Lite Version 3.0 software
(Life Sciences International Ltd., Basingstoke, UK).

Calcineurin Activity
The Calcineurin Cellular Activity Assay Kit (Calbiochem, San Diego, CA) was
used to determine the activity of calcineurin under various treatment condition. 4.5x106
Jurkat cells (at a density of 4x105 cells/mL) were pretreated with doses of CSA or
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FK506 for 30 minutes at 37oC followed by stimulation with PMA and A23187 (as
described above) for 0 minutes, 5 minutes, 10 minutes, 20 minutes, or 30 minutes. Cells
were harvested, washed, and lysed according to kit instructions. The harvested “high
speed supernatant” was desalted using Econo-Pac® 10DG Columns (Bio-Rad
Laboratories). Trace contaminating salts were determined to be absent from the
desalted samples using the GREEN™ reagent as described in the assay kit. Desalted
“high speed supernatants” were assayed for calcineurin phosphatase activity as
described by the manufacturer’s instructions. Colorimetric reactions were read on a
Labsystems Multiskan MCC/340 microplate reader (Molecular Devices Corporation) and
data was analyzed using the Genesis Lite Version 3.0 software (Life Sciences
International Ltd.).
Statistical Analyses
For TCRBV alterations in response to CSA and FK506, bivariate fit statistical
analysis was employed. One-way analysis of variance with Tukey’s post-hoc test was
performed for all other statistical analyses.
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RESULTS
Cyclosporin A and FK506 differentially impact T cells bearing specific T cell
receptors.
In order to assess any alterations in the T cell receptor beta variable (TCRBV)
repertoire associated with the administration of cyclosporin A (CSA) or

Table 1: In vivo TCRBV expression changes in response to increases in FK506 and CSA
dosages.
Opposite trends were observed for the changes in TCRBV repertoire expression in response to
the immunosuppressive agents FK506 and CSA. Results shown are derived from analysis of 5
patients, 11-14 time points/patient totaling 70 separate observations, each performed in triplicate.
Reported p-values are indicative of statistical significance with a confidence interval of at least
95%, or p<0.05.

tacrolimus (FK506), human T cells were isolated from allogeneic peripheral
(hematopoietic) stem cell transplant patients weekly up to 100 days post transplant. We
hypothesized that both CSA and FK506 would have a “global” immunosuppressive
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effect on the T cells within the hematopoietic stem cell recipients. Analysis of the
TCRBV repertoire, however, demonstrated polarized responses of T cells to these two
agents (Table 1). When TCRBV expression was analyzed in response to FK506, a
predominant suppression was observed in its effects on T cells bearing specific
receptors, specifically TCRBV1-6, 11-16, and 20-23. However, when samples were
analyzed for the effect induced by CSA, an increase in the expression of TCRBV4-6,
11-13, 15, 16, and 21 was observed. The in vivo concentration of CSA and FK506 can
be impacted by various factors. Calcium channel blockers, anti-fungal agents,
antibiotics, and anti-inflammatory drugs are among the agents known to potentially
increase the serum concentrations of CSA and FK506 (according to manufacturer).
Anticonvulsants, grapefruit, and dietary supplements, such as St. John’s Wort, may
have the opposite effect and decrease serum concentrations of CSA and FK506
(according to manufacturer). To ensure that such metabolic alterations were not causing
artificial changes in the expression of the TCRBV repertoire, serum concentrations of
CSA and FK506 were also analyzed for their impact on the TCRBV expression levels.
The analyses using either the actual dosage level (Table 1) or the serum level (data not
shown) yielded similar results.
Cyclosporin A and FK506 affect on cell viability.
It is possible that the different TCRBV usage between CSA and FK506 in vivo
was due to a differential effect of the two agents on T cell viability. In order to assess
this potential difference in viability in vitro studies
were performed using the T–cell derived Jurkat
cell line. Jurkat cells were pretreated with a range
of concentrations of CSA (0-400ng/mL) or FK506
(0-20ng/mL) prior to stimulation with PMA and
A23187 and then cultured for 24 hr, 36 hr, or 48
hr at which time 7-AAD staining was done to
Figure 2: Effects of CSA and FK506 on

access

viability.

As

depicted

in

Figure

2,

Jurkat cell viability as measured by 7-AAD

significant differences were not obtained in cell

exclusion.

viability, despite the presence of CSA or FK506.

Results depicted are the means of two independent experiments. Abbreviations: no Rx, no
addition of immunosuppressive agent; CSA, plus the addition of cyclosporin A; FK506, plus the
addition of FK506. Experiments depicted are for target therapeutic doses of CSA (200ng/mL) and
FK506 (10ng/mL).
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Similar results were seen when cells were pretreated with any of the following
concentrations of immune suppressive agents: one-half therapeutic dose (CSA:
100ng/mL, FK506: 5 ng/mL), therapeutic dose (CSA: 200 ng/mL, FK506: 10 ng/mL), or
twice the therapeutic dose (CSA: 400 ng/mL, FK506: 20 ng/mL), or when viability was
assessed after 24 hours or 48 hours of culture. At 24 hr, 36 hr, and 48 hr, a trend of
higher cell death was observed with the pretreatment of both the therapeutic and twice
the therapeutic doses of CSA compared to FK506. These difference, however, were not
found to be statistically significant. Similar results were also observed when viability was
assessed by trypan blue exclusion.
Treatment with Cyclosporin A and FK506 do not alter the proliferation of Jurkat
cells.
With viability not noticeably altered by treatment with either CSA or FK506, the
proliferative ability of the treated cells was examined next.

Figure 3: Effects of CSA and FK506 on Jurkat cell proliferation as determined by CFSE cellular
membrane labeling.
The proliferative index, or the sum of the cells in all generations divided by the computed number of
original parent cells present at the start of the experiment, was determined for all samples from two
independent experiments with their means +/- SEM indicated. The proliferative index is a measure
of the increase in cell number in the culture over the experimental period. No statistically significant
differences were observed for proliferation experiments. Abbreviations: no Rx, no addition of
immunosuppressive agent; CSA, plus the addition of cyclosporin A; FK506, plus the addition of
FK506. Experiments depicted are for target therapeutic doses of CSA (200ng/mL) and FK506
(10ng/mL).
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The proliferative index is a calculated measurement of the increase observed in
the culture’s cell number over the course of the experiment. As depicted in Figure 3, no
statistically significant difference in cellular proliferation was observed when cells were
treated with either CSA or FK506. Additionally, no statistically significant differences
were detected when the cells were treated with a range of concentrations of CSA or
FK506 (one-half therapeutic dose, therapeutic dose, or twice the therapeutic dose) or
when cells were permitted to proliferate for 24, 36, or 48 hours.
Cyclosporin A and FK506 inhibit IL-2 production in Jurkat cells.
CSA and FK506 are known to inhibit IL-2 production by T cells

13-16

. While high

IL-2 levels were produced by untreated
(without the addition of CSA or FK506)
stimulated

Jurkat

cells,

significant

differences were observed between the
levels of IL-2 produced by treated and
untreated samples, regardless of the
concentration of the agents used (onehalf therapeutic dose, therapeutic dose
(Figure 4), or twice the therapeutic dose)
Figure 4: Effects of CSA and FK506 on IL-2 secretion
by Jurkat cells as measured by ELISA.

or the length of the culture period (24, 36,
or 48 hours). In addition, there was no
statistically significant difference found in

Data is representative of the means of two
independent experiments +/- SEM. Statistical
significances are noted. Dotted lines indicate assay
limit of detection. Abbreviations: no Rx, no addition of
immunosuppressive agent; CSA, plus the addition of
cyclosporin A; FK506, plus the addition of FK506.
Experiments depicted are for target therapeutic
doses of CSA (200ng/mL) and FK506 (10ng/mL).

the

suppression

of

IL-2

production

between CSA and FK506 treatments.
Both agents were found to inhibit IL-2
production equally and were determined
to not interfere with the in vitro IL-2
detection assay.
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Calcineurin activity is inhibited equally by both CSA and FK506.
The inhibition of IL-2 production by
both CSA and FK506 is known to occur by
the binding of these agents to their binding
partners

cyclophilin

and

FK-binding

protein, respectively, and their subsequent
inhibition of calcineurin

7-12

. Therefore, the

activity of calcineurin in Jurkat cells treated
with CSA or FK506 was measured in vitro.
Figure 5: Effects of CSA and FK506 on calcineurin Jurkat
activity in Jurkat cells.

cells

were

treated

with

the

therapeutic doses of CSA and FK506 and
stimulated with PMA and A23187 calcium

Data is representative of the means of two
independent experiments +/- SEM. Statistical
significances are noted. Dotted lines indicate
assay limit of detection. Abbreviations: no Rx, no
addition of immunosuppressive agent; CSA, plus
the addition of cyclosporin A; FK506, plus the
addition of FK506. Experiments depicted are for
target therapeutic doses of CSA (200ng/mL) and
FK506 (10ng/mL).

ionophore for 5, 10, 20, or 30 minutes prior
to

cellular

protein

collection.

As

anticipated, cells treated with either CSA or
FK506 resulted in a significant decrease in
the activity of calcineurin compared to
untreated

control

cells

(Figure

5).

Significant differences, however, were only observed at the five-minute time point and
no significant difference was ever observed between CSA and FK506. Additionally, it
was determined that neither agent interfered with the detection of the in vitro calcineurin
activity assay.
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DISCUSSION
Despite the fact that both CSA and FK506 inhibit IL-2 production by T cells,
different effects were observed on the T cell receptor repertoire in the presence of these
immunosuppressive agents in peripheral blood samples from patients undergoing
allogeneic peripheral blood stem cell transplant. This observation, however, cannot be
attributed to differences in the viability, proliferation, IL-2 production, or calcineurin
activity of Jurkat cells treated with CSA versus FK506 in vitro.
Since the in vivo setting is rather complex in experimental variables, we chose to
perform in vitro experiments using the Jurkat human T-cell line. T helper cells have
been documented to be the main target of CSA and FK506 (according to
manufacturers), and this was an additional reason for using Jurkat cells (CD4+) in in
vitro experiments. An additional advantage to using this cell line is that Jurkat cells
express TCRBV8

19

, a TCR that showed varied responses to CSA compared to FK506

(Table 1). A decrease in TCRBV8 was seen with CSA whereas no significant response
was observed with FK506 treatment.
Two previous reports detailed the changes in the expression of TCRBV8 in
response to CSA therapy. Fischer et al., described an increase in TCRBV8.5 in mice
following administration of CSA therapy

21

and Severino et al., reported an increase in

the expression of TCRBV8 in CSA-induced murine syngeneic graft-versus-host disease
22

. Although it has been determined that great homology exists between the TCRBV

families in mice and humans

23

, there is no report of TCRBV8.5 in humans

24

, making

these specific murine studies difficult to directly compare to our study. They do,
however, suggest that CSA can exert differed effects on cells carrying a specific
TCRBV.
While the inhibition of IL-2 production through the blocking of calcineurin is the
accepted mechanism of action for both CSA and FK506

13-16

, a report by Marton et al.,

in yeast cells has alluded to the possible existence of a calcineurin-independent
pathway for FK506-mediated effects

25

. Using a yeast model and various mutants, they

demonstrated that many of the GCN-4 regulated genes were induced by exposure to
FK506. GCN-4, a c-Jun/c-Fos homolog, is a eukaryotic transcriptional activator protein
that is primarily responsible for the regulation of biosynthetic genes in Saccharomyces
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cerevisiae

26-29

. Although different model systems, both humans and yeast are

eukaryotic and a crossover in this alternative pathway may exist. There is also evidence
that there is different transcriptional control in humans depending upon the TCRBV
usage, with factors such as the promoter and non-coding (spacer) regions contributing
to these differences 30-35.
Our results argue that a secondary mechanism of action for the altered TCRBV
repertoire must exist for these immunosuppressive agents as none of the above
mentioned parameters, including calcineurin activity, IL-2 production, cell viability and
proliferation, exhibited differing effects in response to CSA and FK506 treatments. While
the possibility still exists due to our small sample size, we do not believe that these
results are attributed to donor variability as results reported were observed across the
population of patient/donor pairs, not unique to any single case. Future investigation into
alternative mechanisms may yield a clearer understanding of the cellular events
responsible for the varying effect on T cells by the related immunosuppressive agents
CSA and FK506.
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CHAPTER 6

GENERAL CONCLUSIONS AND DISCUSSION
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The overall goal of this investigation was to identify and study the role of specific
T lymphocytes following human hematopoietic stem cell (HSC) transplant. Current
literature has stressed the importance of T lymphocytes in this setting but has thus far
focused on the identification of specific families of T lymphocytes as it pertains to the
occurrence of graft-versus-host disease (GVHD). Several novel findings have emerged
from our investigation: (1) a panel of oligonucleotides has been developed to accurately
and efficiently detect expression of all known human TCRBV regions, (2) specific
TCRBV families are associated with reactivation of cytomegalovirus (CMV) post HSC
transplant with many of these same TCRBV families also being associated with the
occurrence of GVHD, (3) the TCRBV repertoire engrafts in the recipient with a profile
more similar to that found in the donor as opposed to that found in the recipient prior to
transplant, and (4) the similar immunosuppressive agents, cyclosporin A (CSA) and
tacrolimus (FK506), differentially alter the TCRBV repertoire with their administration.
Prior investigations have used the TCRBV regions to identify specific T cells
involved in various settings, such as with GVHD. While our study had initially planned
on utilizing prior existing technology to further investigate the role of T lymphocytes in
the post HSC transplant environment, we were unable to locate a method that
accurately examined all of the TCRBV genes. To address this, we relied on the TCR
gene classification system instituted by the World Health Organization. Using various
sequence databases and strict primer sequence specifications, we were able to develop
a panel of primers that could be used to accurately and efficiently identify all 91 alleles
of the human TCRBV region. Using these primers and sequence specific (TaqMan®
probe) real-time PCR detection, we demonstrated that our system was not only specific
but also efficient and comparable to TCRBV protein expression profiles. The importance
of this technology was realized and has since been protected by both U.S. and foreign
patent applications.
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Once a method was available to accurately identify T cells based upon their
TCRBV expression, we wanted to apply this technology to our specific area of interest,
the post HSC transplant setting. Many prior investigations using human HSC transplant
patients have focused on identifying the T cells associated with GVHD. These studies
relied on “snapshot” sampling, for example collecting a sample early post transplant and
at the time of GVHD diagnosis. Many of these studies also aimed to determine if there
was an association of specific T cells in the peripheral blood (PB) and in the GVHD
tissue lesion, the lesion frequently being a skin biopsy. In these studies, though, such
an association was rarely seen. We believed one explanation for the lack of association
of PB and GVHD lesion TCR repertoires was due to the fact that PB and tissue samples
were drawn simultaneously. This timing of sample procurement would not accounting
for the fact that (1) the development of GVHD is not an instantaneous process and, (2)
the T cells expanded in the PB would traffic to the lesion after expansion, resulting in an
efflux of these cells from the PB and an influx of these cells into the lesion. In our study,
we instituted a serial sampling schedule where baseline samples were collected from
both the donor and recipient prior to transplant, with recipient sample collection
continuing on a weekly basis post HSC transplant, up to day 100. Day 100 was chosen
as our final time point since acute GVHD, by definition, occurs no later than day 100
post transplant. The chronic form of the disease may not appear for several months to
years after transplant, yielding a sampling schedule not conducive to our time frame.
While our initial plans of obtaining a GVHD lesion sample at time of diagnosis was not
fulfilled, we were able to collect PB samples from our study patients on a regular basis.
This led us to analyze not only what TCRBV families were involved in GVHD but also
those families involved in other post HSC transplant events.
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Our HSC transplant center here at West Virginia University has frequently
observed the association of CMV reactivation post transplant and the subsequent
development of GVHD. Although there are several studies that support the notion that a
link does indeed exist between CMV and GVHD, no such study has looked at the
similarity in TCRBV expression with these two complications post HSC transplant. We
not only determined which TCRBV families were associated with CMV reactivation in
this setting, but were also able to draw parallels between many of these TCRBV families
and those also associated with GVHD. Further, many of the families we determined to
be associated with CMV reactivation have been previously shown to be CMV reactive in
what are considered otherwise healthy human donors. Not only is our study the first to
identify those TCRBV families associated with CMV reactivation post HSC transplant,
we were also the first to show an overlap in the TCRBV families associated with CMV
and GVHD.
Since we had serial TCRBV analysis of our patients, we utilized our data sets to
determine if the transplanted donor HSCs developed with a phenotype more
reminiscent of that found in the recipient prior to transplant or with greater similarity to
the mature profile found in the donor. We expected that the influence of the recipient’s
environment on these developing HSC would consequently lead to the development of
a TCRBV repertoire more reminiscent of that found in the recipient prior to transplant.
However, our samples exhibited an engraftment profile with a greater correlation to that
found in the donor prior to transplant compared to that initially found in the recipient.
While we had a small sample population (n=4) these are the first results we can find to
investigate this question. Furthermore, we do not believe these results are attributable
to analysis of mature donor T cells initially found within the graft as the patients that
exhibited this trend all received Campath-1H therapy that specifically targets the
destruction of any residual mature donor T cells found within the graft. The one patient
that exhibited a greater correlation to herself than to that found in the donor at the
conclusion of the study was the sole patient in our population that did not receive the
Campath-1H regimen, but received an alternate myeloblative regimen. These results
are preliminary but do inspire further thoughts into the contribution of the recipient
environment on the development of the transplanted donor cells.
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As a consequence of serial time point analysis and the treatment of all of our
study participants with immunosuppressive agents, we observed that the highly similar
immunosuppressive agents CSA and FK506, which are both calcineurin inhibitors, had
polarized effects on the TCRBV repertoire. FK506 administration resulted in an overall
suppression of TCRBV expression while the opposite effect was observed with CSA
therapy. Interesting to this observation is the fact that in the HSC transplant setting,
FK506 administration is customarily reserved for situations in which greater genetic
disparity exists between the recipient and donor, with CSA administration typically being
utilized for those transplants with fewer mismatch-related complications anticipated.
Potentially our observation could help to explain the immunology behind such
pharmacological strategies. To try to determine if there was some facet of the known
immunosuppression mechanism of these two agents responsible for contributing to our
observed difference, we examined the effect of these two agents in vitro using the
human Jurkat T cell line. We determined that while both of these agents did decrease
the activity of calcineurin and, subsequently inhibited the production of IL-2, they did so
equally well.
Taken together, we feel we have contributed to the understanding of the role of
specific T cells in the post HSC transplant environment. While our sample population
was large compared to prior similar investigations, we hope that future studies will
confirm our results using larger sample populations. Not only has our work contributed
to the field of HSC transplantation but also to the field of immunology as a whole. Our
TCRBV expression technology vastly improves upon that which existed in the field prior
to our entry, and we anticipate the application of our technology to many areas of
immunological interest, including the usage of specific TCRBV families during infectious
disease, autoimmune disease, graft rejection, and even cancer therapy and graftversus-leukemia effect. Future work will hopefully elucidate a greater understanding of
the association of CMV reactivation and GVHD with the identification of specific
antigens driving these T cell responses. The possible existence of a secondary
mechanism of action for CSA and FK506 will also be investigated in the future and will
help to encourage a re-thinking of present treatment strategies. Should all patients not
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be given FK506 as opposed to the present directing of patients into treatment groups
based upon the relation of the donor?
In conclusion, one of the most interesting facets of this project was the identity it
took over time. As data was generated and the novelties of patient sampling became
more apparent, areas that were initially anticipated to be of less interest became
increasingly curious and of interest. It reasons that one of the facets to being a good
scientist is to set aside pre-conceived notions and approach the data with neutrality. By
these means truths are discovered and the field of science marches onward. After all,
“the true scientist never loses the faculty of amazement”.
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APPENDIX
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Amplification efficiency analysis
Amplification efficiency analysis for TCRBV primers was determined using the following
formula:
Efficiency (E) = (10-1/slope)-1
Where the slope is determined by plotting the Ct value (Y-axis) vs log [cDNA] (X-axis)
using 10-fold dilutions of template

Example of equation usage:
slope of amplification plot is determined to be -3.59
E = (10-1/-3.59)-1
E=10 0.28-1
E=1.90-1
E=0.90, or 90% efficient

Reference: Rasmussen, R. (2001) Quantification on the LightCycler. In Meuer, S.,
Wittwer, C. and Nakagawara, K. (eds), Rapid Cycle Real-time PCR, Methods and
Applications. Springer Press, Heidelberg, pp. 21-34.
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IOTest™ Beta Mark TCR VB Repertoire Kit
The IOTest™ Beta Mark TCR VB Repertoire Kit (Beckman Coulter, Inc.,
Fullerton, CA) was used for TCRBV protein expression analysis. Samples were
prepared according to the manufacturer’s directions using 5 x 105 buffy coat white blood
cells per sample, prepared as previously described. To identify CD3+ cells for TCR
analysis an anti-CD3 PC5 antibody and an IgG1 PC5 isotype antibody, each at a
volume of 10µl/sample (Beckman Coulter, Inc.) were used as described in the IOTest™
kit specifications. Stained samples were then washed in 1X PBS prior to fixation in 500
µl of 1% paraformaldehyde. All prepared samples were analyzed by flow cytometric
analysis using a FACScan (Becton Dickinson, Franklin Lakes, NJ), which had been
calibrated using three color Calibrite Beads (Becton Dickinson) and FACSCOMP
software (Becton Dickinson). A total of 5,000 live-gated CD3+ cells were collected for
analysis of each IOTest™ TCR BV expression sample. SSC and FSC data were
acquired in the linear mode and the FL1, FL2, and FL3 parameters were collected
logarithmically. Data analysis was performed using Windows Multiple Document
Interface (WinMDI) version 2.8 (Joseph Trotter, The Scripps Research Institute,
http://facs.scripps.edu/spftware.html).

Gating of CD3+ lymphocytes for IOTest TCRVB antibody analysis.
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IOTest TCRVB antibody flow cytometric results expressed as percent CD3+ cells.
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